

Executable models of pathways built using single-cell RNA seq data reveal immune signaling dysregulations in people living with HIV and atherosclerosis

Mukta G. Palshikar¹, Rohith Palli², Alicia Tyrell³, Sanjay Maggirwar⁴, Giovanni Schifitto^{5, 6}, Meera
V. Singh^{5, 8}, and Juilee Thakar^{1, 7, 8, 9**}

**Correspondence: Juilee_Thakar@URMC.Rochester.edu

¹ Biophysics, Structural, and Computational Biology Program, University of Rochester School of
Medicine and Dentistry, Rochester, USA. ⁶ Department of Biostatistics and Computational
Biology, University of Rochester School of Medicine and Dentistry, Rochester, USA. ⁷
Department of Microbiology and Immunology, University of Rochester School of Medicine and
Dentistry, Rochester, USA. ⁸ Department of Biomedical Genetics, University of Rochester
School of Medicine and Dentistry, Rochester, USA

Full list of author information is available at the end of the article

Abstract:

Background: Atherosclerosis (AS)-associated cardiovascular disease is an important cause of mortality
in an aging population of people living with HIV (PLWH). This elevated risk of atherosclerosis has been
attributed to viral infection, prolonged usage of anti-retroviral therapy, and subsequent chronic
inflammation.

Methods: To investigate dysregulated immune signaling in PLWH with and without AS, we sequenced
9368 peripheral blood mononuclear cells (PBMCs) from 8 PLWH, 4 of whom also had atherosclerosis
(AS+). To develop executable models of signaling pathways that drive cellular states in HIV-associated
atherosclerosis, we developed the single-cell Boolean Omics Network Invariant Time Analysis

23 (scBONITA) algorithm. ScBONITA (a) uses single-cell RNA sequencing data to infer Boolean rules for
24 topologically characterized networks, (b) prioritizes genes based on their impact on signaling, (c)
25 performs pathway analysis, and (d) maps sequenced cells to characteristic signaling states. We used
26 scBONITA to identify dysregulated pathways in different cell-types from AS+ PLWH and AS- PLWH.
27 To compare our findings with pathways associated with HIV infection, we used scBONITA to analyze a
28 publicly available dataset of PBMCs from subjects before and after HIV infection. Additionally, the
29 executable Boolean models characterized by scBONITA were used to analyze observed cellular states
30 corresponding to the steady states of signaling pathways

31 **Results:** We identified an increased subpopulation of CD8+ T cells and a decreased subpopulation of
32 monocytes in AS+ PLWH. Dynamic modeling of signaling pathways and pathway analysis with
33 scBONITA provided a new perspective on the mechanisms of HIV-associated atherosclerosis. Lipid
34 metabolism and cell migration pathways are induced by AS rather than by HIV infection. These pathways
35 included AGE-RAGE and PI3K-AKT signaling in CD8+ T cells, and glucagon and cAMP signaling
36 pathways in monocytes. Further analysis of other cell subpopulations suggests that the highly
37 interconnected PI3K-AKT signaling pathway drives cell migratory state in response to dyslipidemia.
38 scBONITA attractor analysis mapped cells to pathway-specific signaling states that correspond to distinct
39 cellular states.

40 **Conclusions:** Dynamic network modeling and pathway analysis with scBONITA indicates that
41 dysregulated lipid signaling regulates cell migration into the vascular endothelium in AS+ PLWH.
42 Attractor analysis with scBONITA facilitated pathway-based characterization of cellular states that are
43 not apparent in gene expression analyses.

44 **Keywords:** single-cell RNA sequencing; Boolean networks; HIV; atherosclerosis; pathway analysis;
45 network modeling

46 **Background**

47 Human immunodeficiency virus (HIV) infection greatly increases the risk of atherosclerosis (AS)
48 associated cardiovascular disease (CVD), which is a leading cause of morbidity and mortality in persons
49 living with HIV (PLWH) (1-4). Several factors contribute to this elevated risk of AS. PLWH have a
50 higher prevalence of traditional risk factors for AS such as dyslipidemia, diabetes, hypertension, and
51 smoking (5-9). In addition, the off-target effects of certain classes of antiretroviral drugs lead to an
52 increase in traditional metabolic risk factors such as dyslipidemia, weight gain, and metabolic syndrome
53 (9, 10). However, PLWH have an elevated risk of developing CVD even when controlling for these risk
54 factors (4, 11, 12). Finally, HIV infection itself causes metabolic changes leading to a pro-atherogenic
55 inflammatory environment in the vasculature (13-16).

56 HIV infection and long-term antiretroviral therapy modulate signaling dynamics, leading to changes in
57 the composition of peripheral blood mononuclear cells (PBMCs) and in the expression of functionally
58 important molecules in these cells (17). HIV infection mediates an array of molecular signaling pathways,
59 including inflammasome activation, cell migration and apoptosis. These signaling pathways contribute to
60 immune cell activation and inflammation in the vasculature (18). Biomarker studies also highlight the
61 importance of these processes in atherogenesis, especially in the context of activated
62 monocyte/macrophages and T cells (14-16). CD8⁺ T cells contribute to the atherogenic environment by
63 cytokine secretion, secretion of cytotoxic granules and formation of the necrotic core of atherosclerotic
64 plaques (reviewed in (19)). Monocyte/macrophages migrate into the intima and eventually form
65 apoptotic, atherosclerotic plaques (reviewed in (20)). The interplay between immune signaling pathways
66 and immune cell activation and inflammation in the context of HIV infection still requires further
67 investigation. Single-cell measurements of expression profiles allow the investigation of these
68 perturbations simultaneously. To investigate the mechanistic link between HIV infection and
69 atherosclerosis, we used the 10X Genomics platform to sequence ~10,000 PBMCs from 8 PLWH, 4 of
70 whom have atherosclerosis.

71 Typically, analysis of single cell RNA sequencing (scRNA-seq) data uses clustering methods to define
72 cell subpopulations, followed by differential expression and gene set overrepresentation analysis (ORA)
73 to estimate modulation of molecular pathways in the condition under study. This standard analysis
74 approach discounts pathway topology and falls short of connecting molecular state to cellular state.
75 Furthermore, ORA ignores synergistic interactions among genes by, in effect, treating genes as
76 independent and equal, resulting in a failure to correctly estimate the significance of pathways (21).

77 Discrete-state network modeling facilitates prioritization of experiments by using simple logic rules such
78 as ‘AND’ or ‘OR’ to explicitly define signal integration, enabling investigation of crosstalk and
79 downstream events as shown in our previous studies. Previously, we have extensively used discrete-state
80 network modeling to investigate virus infections and have experimentally validated the predictions (22,
81 23). We have also developed an algorithm to perform Boolean rule inference and pathway analysis using
82 bulk transcriptomic data. This algorithm has been rigorously tested and compared across other widely
83 used gene-set enrichment methods (24). Here, we expand our discrete-state modeling method and present
84 single-cell Boolean Omics Network Invariant-Time Analysis (scBONITA) to (a) infer Boolean rules (e.g.,
85 “AND”, “OR”) describing signal integration for gene interactions described by the pathway topologies
86 from scRNA-seq data and (b) use these inferred regulatory rules to identify condition-specific
87 dysregulated pathways and to prioritize genes/proteins for further investigation. Instead of simply
88 returning a list of dysregulated pathways and associated p-values, scBONITA returns precise modes of
89 dysregulation, captured by node-level impact scores that quantify the contribution of each node (a gene or
90 protein) to the overall dysregulation of a pathway, measured by *in silico* perturbation and simulation that
91 matches experimental conditions. *In silico* simulation and perturbation of molecular pathways allows the
92 use of scBONITA as a powerful hypothesis-generating tool.

93 We demonstrate that scBONITA can infer dysregulated pathways from single-cell RNA sequencing
94 (scRNA-seq) data upon HIV infection using publicly available data and in the context of HIV-associated
95 atherosclerosis using data presented in this work. scBONITA identifies dysregulated cell migration and

96 lipid metabolism related pathways such as PI3K signaling, leukocyte transendothelial migration, and
97 AGE-RAGE signaling in the subpopulations of CD8+ T cells and monocytes, known to be implicated in
98 HIV-associated atherosclerosis. ScBONITA identifies genes, such as the PI3K and PLC genes, which
99 have high impacts on signal flow through the signaling pathways named above. CD4+ T cells and B cells
100 are also known to play significant roles in the development of atherosclerosis and cardiovascular disease
101 (25-35). In both subpopulations, scBONITA identified pathways that were linked to cell migration (such
102 as proteoglycans in cancer and the regulation of actin cytoskeleton pathways), lipid metabolism (PI3K-
103 Akt signaling, phosphatidylinositol signaling) and pathways linked to intercellular communication (such
104 as the chemokine signaling, apelin signaling, and cytokine-cytokine receptor interaction pathways).

105 Furthermore, we used a publicly available dataset of PBMCs from persons before and after HIV infection
106 to show that cell migration pathways are also dysregulated in the early stages of HIV infection, indicating
107 a role for these pathways in both the antiviral response and in subsequent AS (36). We also present a
108 novel method for mapping cells to pathway-specific signaling states using rules identified by BONITA. In
109 conclusion, scBONITA is a powerful tool that can be used for network modeling using single-cell RNA-
110 seq data. In this study, we demonstrate that scBONITA provides an insight into the mechanisms of HIV-
111 associated atherosclerosis at the single-cell level.

112 **Methods**

113 ***Participant cohort summary, sample collection, and storage***

114 Eight men living with HIV and ≥ 50 years of age on stable combined antiretroviral therapy (cART) for
115 at least 1 year and with viral load ≤ 50 copies/mL were recruited. All methods were carried out in
116 accordance with University of Rochester guidelines and regulations, and all experimental and study
117 protocols were approved by the University of Rochester Institutional Review Board (#RSRB00063845).
118 Informed consent was obtained from all subjects. Individuals were classified as having atherosclerosis

119 (AS+) if they had plaques on the carotid arteries on ultrasound imaging. Four of the 8 subjects were
120 assigned as AS+ and had plaques in both right and left carotid arteries. AS- subjects were aged between
121 47 and 57 and AS+ subjects were aged between 51 and 66. AS+ subjects had mean serum cholesterol of
122 161.5 mg/dl ($\sigma = 40.9$) and mean serum high-density lipid HDL of 54.7 mg/dl ($\sigma = 16.3$). AS- subjects
123 had mean serum cholesterol of 167.7 mg/dl ($\sigma = 57.2$) and mean serum high-density lipid HDL of 51
124 mg/dl ($\sigma = 7.7$). AS- subjects and AS+ subjects had a mean CD4+ T cell count of 518.5 cells/ μ l ($\sigma = 347.8$
125 cells/ μ l) and 838.7 cells/ μ l ($\sigma = 514.5$ cells/ μ l) respectively. 30 mls of blood per study participant was
126 collected in ACD vacutainers and was processed within 2 - 3 hours of collection. Peripheral Blood
127 Mononuclear Cells (PBMCs) were isolated using Ficoll density gradient centrifugation. 5 million PBMCs
128 were preserved using RNeasy (Thermo Fisher) and were used for scRNA-seq. De-identified subject
129 information is available in Supplementary File 1, Supplementary Figure 1.

130 ***Single-cell sequencing and data processing***

131 Frozen vials containing cells in RNeasy were thawed quickly in a 37-degree water bath. Cell suspension
132 was transferred to a 15ml conical tube. 10 ml PBS/2% FBS was slowly added. Samples were centrifuged
133 at 1600rpm for 6 min. Washes were repeated for an additional 2 times for a total of 3 washes. Using the
134 MACS Miltenyi Biotec Dead Cell removal kit (PN130-090-101), dead cells were removed using
135 manufacturer's recommendations. Cells were counted and cellular suspensions were loaded on a
136 Chromium Single-Cell Instrument (10x Genomics, Pleasanton, CA, USA) to generate single-cell Gel
137 Bead-in-Emulsions (GEMs). ScRNA-seq libraries were prepared using Chromium Single-Cell 3' Library
138 & Gel Bead Kit (10x Genomics). The beads were dissolved, and cells were lysed per manufacturer's
139 recommendations. GEM reverse transcription (GEM-RT) was performed to produce a barcoded, full-
140 length cDNA from poly-adenylated mRNA. After incubation, GEMs were broken, and the pooled post-
141 GEM-RT reaction mixtures were recovered, and cDNA was purified with silane magnetic beads
142 (DynaBeads MyOne Silane Beads, PN37002D, ThermoFisher Scientific). The entire purified post GEM-
143 RT product was amplified by PCR. This amplification reaction generated sufficient material to construct a

144 3' cDNA library. Enzymatic fragmentation and size selection was used to optimize the cDNA amplicon
145 size and indexed sequencing libraries were constructed by End Repair, A-tailing, Adaptor Ligation, and
146 PCR. Final libraries contain the P5 and P7 priming sites used in Illumina bridge amplification. Sequence
147 data was generated using Illumina's NovaSeq 6000. Approximately 2000 cells were sequenced from each
148 subject. Cell Ranger (version 2.1.1; 10x Genomics) was used for demultiplexing and alignment with
149 default parameters. Reads were aligned to the human reference genome GRCh38 (Ensembl 93). The
150 Seurat R package (37) was used to further process the gene counts obtained from the CellRanger pipeline.
151 Cells that express < 200 genes, > 2500 genes, and > 5% mitochondrial genes were filtered out. Genes
152 expressed in < 3 cells were filtered out. Gene counts were per-cell normalized and log₂-transformed.
153 These preliminary filtering and selection procedures yielded a set of 9368 sequenced cells, approximately
154 equally distributed between subjects (and hence conditions), and 14017 genes. Note that sample
155 collection, processing and sequencing were performed in one batch, leading to extremely high-quality
156 data where no subject specific patterns were observed.

157 ***Classification into subpopulations using modularity-optimized***

158 ***Louvain community detection, and cluster labeling***

159 Cells were classified into subpopulations using modularity optimized community detection, implemented
160 in the Seurat R package (37). 664 highly variable genes were used to identify 10 principal components
161 that explained the majority of variance in the data. These principal components were used to cluster the
162 data. Clustering yielded 16 subpopulations. Cluster markers were identified using MAST (38). As
163 suggested in (39), CIBERSORT (40) was used to "deconvolute" the average gene expression of each
164 cluster into the constituent canonical cell types. A reference expression set of 22 immune cell types and
165 547 genes was used (40). Over-representation analysis was performed using the implementation of the
166 hypergeometric test in the R package clusterprofiler with Kyoto Encyclopedia of Genes and Genomes

167 (KEGG) gene sets downloaded from MSigDb (41-43). Gene sets were identified as significantly over-
168 represented if the Bonferroni-adjusted p-value was < 0.05 .

169 ***scBONITA algorithm for development of discrete-state models of*** 170 ***pathways***

171 **Network topologies:** ScBONITA infers Boolean regulatory rules/ logic gates for directed
172 networks wherein nodes represent genes and edges represent the regulatory relationships between those
173 genes. These networks contain edge annotations denoting activation/inhibition relationships between
174 nodes, which are exploited by scBONITA to restrict the search space for rule inference to sign-compatible
175 analyzing functions. Such network models of biological pathways are commonly obtained from pathway
176 databases such as KEGG and WikiPathways (43-45). ScBONITA offers an interface to KEGG and
177 WikiPathways databases that allows automated download and processing of user-specified networks.
178 Users can also provide custom networks in graphml format.

179 **Boolean rule determination from scRNA seq data:** The underlying principle of
180 scBONITA is that cross-sectional measurements of cells by scRNA-seq data represent states of an
181 underlying dynamic biological process. scBONITA's rule determination (scBONITA-RD) algorithm,
182 which has been extended from our previous BONITA algorithm exploits this property to infer Boolean
183 rules for an input biological network, using a combination of a genetic algorithm (GA) and a node-wise
184 local search (46).

185 The global search using GA infer a single candidate rule set that adequately describes the input data with
186 respect to the network topology with minimum error (24, 47). The function to be minimized is:

$$187 \sum_{c=1}^{cells} \min \left(\sum_{n=1}^{nodes} |E_{c,n} - A_{c,n,a}| \forall a \text{ in } T_c \right)$$

188 Where, c from 1 to $cells$ iterates over the number of cells in the training dataset, n iterates from 1 to
189 number of *nodes* in the network, $E_{c,n}$ is the binarized expression of node n in cell c , $A_{c,n,a}$ is the value of
190 node n in the attractor a reachable from cell c , and T_c is the attractor reachable from c . Note that T_c may
191 have multiple repeating states in a limit cycle or only one steady state, i.e., it may be a singleton attractor.
192 T_c is obtained after simulating the network with the candidate rule set for 100 time-steps, which causes
193 the simulation to reach an attractor state for all tested networks.

194 The minimum error rule set identified using the above-described genetic algorithm strategy is further
195 refined by a node-level local search that sequentially optimizes the rule for each node keeping the rules
196 for all other nodes in the network constant. An optimal set of rules for a node n is obtained by minimizing
197 the function

$$198 \quad \sum_{c=1}^{cells} \min (|E_{c,n} - A_{c,n,a}| \forall a \text{ in } T_c)$$

199 where variables and constants are same as described above.

200 Several rules may satisfy the termination criteria with equal errors. The local search thus returns a set of
201 equivalent rules that all satisfactorily explain the observed state in the experimental data. This set of rules
202 is referred to as the equivalent rule set (ERS) in the text.

203 **Pathway analysis (PA) with scBONITA:** scBONITA performs pathway analysis in a two-
204 step process. In the first step, importance scores for each node in the biological network under
205 consideration are calculated. In the second step, a pathway modulation metric incorporating both
206 experiment-specific fold changes and the node importance scores calculated in step 1 is calculated.

207 scBONITA quantifies the influence I_n of a node n over the state of the network by quantifying the overall
208 effect of its perturbation on that network. This is achieved by simulating knock-in and knock-out of that
209 node.

210
$$I_n = \sum_{c=1}^{cells} |KI_{c,n} - KO_{c,n}| * Uncertainty\ Factor$$

211 where $KI_{c,n}$ and $KO_{c,n}$ are the discrete expression vectors of network nodes in the attractors reached after a
212 simulation starting from cell c where the node under consideration n is knocked in and knocked out
213 respectively. The uncertainty factor is defined as follows:

214
$$Uncertainty\ factor = \frac{|Maximum\ ERS_i| - |Observed\ ERS_i| + 1}{|Maximum\ ERS_i|}$$

215 Where ERS_i is the ERS for a node i , $|Maximum\ ERS_i|$ is the maximum possible size of the ERS for a
216 node i and $|Observed\ ERS_i|$ is the size of the ERS for a node i upon optimization by scBONITA.

217 The uncertainty factor weighs I_n relative to the maximum state space for that node, to capture the
218 uncertainty in the rule determination for that node. The importance scores of the nodes in a network are
219 scaled to $[0, 1]$ by dividing by the maximum calculated importance score for the network under
220 consideration.

221 A pathway modulation metric (M_p) is calculated by weighting the node importance score by the
222 difference between the average gene expression in each group (relative abundance, RA) and the standard
223 deviation of expression of that gene (σ). A p-value is calculated by bootstrapping, where a contrast-
224 specific distribution of weighted importance scores is generated using randomly resampled RA values.
225 Pathways are described in the text as being overall upregulated in a given contrast if the sum of fold
226 changes of all genes in the pathway is positive. Conversely, pathways are described as being
227 downregulated if the sum of fold changes of all genes in the pathway is negative.

228
$$M_p = \sum_{n=1}^{nodes} RA_n * \sigma_n * I_n$$

229 Pathways are described in the text as being overall upregulated in a given contrast if the sum of fold
230 changes of all genes in the pathway is positive. Conversely, pathways are described as being
231 downregulated if the sum of fold changes of all genes in the pathway is negative.

232 **Steady-state analysis with scBONITA:** scBONITA assumes that the observed cellular states
233 are defined by states of multiple dynamic cellular processes or signaling pathways. While observed cells
234 are samples along a dynamic trajectory of signaling cascades, analyzing attractors upon randomly
235 sampling the rules from ERS allows us to investigate most common signaling states of a network under
236 consideration. Hence, we sample ten network specific from the ERS inferred by scBONITA-RD to
237 identify a set of reachable attractors. This is achieved by simulating the network synchronously as
238 performed in other studies (48-51) starting from an observed state (i.e., a cell expression vector) until a
239 steady state (or an attractor cycle) is reached. By starting simulations from expression levels of all cells
240 (all observed states), we can ensure that these simulations cover a large fraction of available state space
241 for a given network. In this way, all reachable attractor states, corresponding to observable signaling
242 states, can be identified. The similarity between cells and attractors is quantified using the Hamming
243 distance. Cells are assigned to the attractor that is most similar to their expression data.

244 **Implementation and availability:** scBONITA is implemented in Python 3 and C. Source code,
245 documentation, and tutorials are available on <https://github.com/Thakar-Lab/scBONITA>.

246 ***Application of scBONITA on a publicly available data set***

247 A scRNA-seq dataset obtained from four persons living with HIV (PLWH) before and during infection
248 was selected to demonstrate the utility of the scBONITA pipeline on other datasets and to compare
249 signaling dysregulations upon atherosclerosis in PLWH with signaling dysregulations upon HIV infection
250 (36). Log2-transformed TPM data and metadata processed and curated by the study authors was collected
251 from the Single-Cell Portal database (https://singlecell.broadinstitute.org/single_cell/study/SCP256). The
252 complete scBONITA pipeline was used to compare samples collected before infection to samples

253 collected 1 year after infection. We retained the cluster labels assigned by the authors of the original
254 study. A set of 210 KEGG networks was used with the scBONITA pipeline. Dysregulated pathways and
255 steady states identified by scBONITA were compared to the original analysis, as described in the results.

256 ***In silico evaluation of scBONITA***

257 To show that scBONITA-RD is robust to training set size, we selected a cluster of B cells from the
258 HIV/AS dataset. This subset of the dataset was manipulated to either downsample or augment the size of
259 the training dataset (number of cells) presented to scBONITA-RD. The training dataset was downsampled
260 to 1% and 50% of the original number of cells for cluster 0 (“B cells naïve – 1”). To augment the dataset
261 and thereby introduce heterogeneity, the dataset was increased to 200% of its original size by adding in
262 cells from a neighboring cluster of B cells. A set of 210 KEGG networks was used to evaluate the sizes of
263 the ERS obtained by scBONITA-RD using these manipulated training datasets. The size of the ERS is
264 used as a proxy for scBONITA’s ability to successfully cut down the state space of the possible rules for
265 each node using cross-sectional scRNA-seq data.

266 **Results**

267 ***Single-cell sequencing identifies 16 transcriptionally distinct cell*** 268 ***subpopulations in PBMCs derived from AS+ and AS- PLWH***

269 To investigate dysregulated immune signaling in People Living with HIV (PLWH), who are at an
270 increased risk of atherosclerosis (AS), we recruited a cohort of eight PLWH, four with carotid plaques on
271 both sides of the arteries (referred here as AS+) and four without carotid plaques (referred as AS-). Lipid
272 profiles and age, both known risk factors for cardiovascular disease, were matched and were not
273 significantly different between subject groups (see Methods, Supplementary File 1, Supplementary Figure
274 1). We used the 10X Genomics platform to profile transcriptional changes in ~1200 peripheral blood
275 mononuclear cells (PBMCs) per subject. This scRNA-seq data was processed using the Cell Ranger and

276 Seurat pipelines (37) as described in the Methods to identify sixteen transcriptionally distinct populations
277 of immune cells (Figure 1A). These clusters were then annotated using CIBERSORT (40) with a dataset
278 of sorted immune cells (Supplementary File 1, Supplementary Figure 2) and by using cell-lineage specific
279 markers (Supplementary Table 1). This scRNA-seq dataset is referred to in the text as the HIV/AS
280 dataset.

281 A population of CD8 T cells/NK resting cells was significantly lower in AS- PLWH and a population of
282 CD14+CD16+ monocytes was significantly higher in AS- PLWH (t-test, $p < 0.05$) (Figure 1B). The
283 cluster-specific differentially expressed genes, or cluster markers, for these populations of CD14+CD16+
284 monocytes and CD8+ T cells/NK resting cells were involved in pathways linked to cell migration, such as
285 the leukocyte transendothelial migration, regulation of actin cytoskeleton, adherens junction, and
286 chemokine signaling pathways (Supplementary Table 1), suggesting that CD8+ T cells/NK resting cells
287 and monocytes have a migratory phenotype. Indeed these cells are known to migrate into intima during
288 the formation of atherosclerotic lesions in the vascular wall (52-58).

289 ***Characterization of peripheral blood mononuclear cells in people*** 290 ***living with HIV with and without atherosclerosis***

291 To characterize the expression differences between these cell types in AS+ and AS- PLWH, differentially
292 expressed (DE) genes were identified using the Wilcoxon test as described in the Methods (selected cell
293 types are shown in Figure 1C-F and complete list of DE genes presented in Supplementary Table 2).
294 Genes were reported as being differentially expressed if the adjusted p-value was < 0.05 and the average
295 absolute log fold-change was > 0.3 (representative cell subpopulations shown in Figure 1C-F). Gene set
296 enrichment analysis was performed as described in the Methods. We used gene sets obtained from KEGG
297 and curated in MSigDb. Complete results of the enrichment analysis are presented in Supplementary
298 Table 2.

299 Considered together, differential expression analysis and gene set enrichment analysis provided insights
300 into the functional differences in cells obtained from AS+ and AS- PLWH. Several genes (and gene sets)
301 related to cell migration and mobility were upregulated in cells derived from AS+ PLWH. MHC Class 1
302 genes (HLA-A, HLA-B and HLA-C) and MHC Class II genes (HLA-DP, HLA-DQ, HLA-DB, and HLA-
303 DR) were upregulated in multiple cell subpopulations. Figure 1E shows the expression of HLA-A and
304 HLA-DRA in B cells naïve -2. Similarly, ITGB2 was upregulated in population a cluster of CD8+ T cells
305 (“T cells CD8 – 3”) derived from AS+ PLWH. These cell-surface proteins are all involved in cell-cell
306 interactions and cellular adhesion.-ITGB2 interacts with ICAM2 expressed on the surface of endothelial
307 cells and is involved in leukocyte transendothelial migration. The actin gene ACTB was upregulated in
308 both populations of naïve B cells and a population of CD8+ T cells derived from AS+ PLWH. Similarly,
309 CXCR4 was upregulated in cells derived from AS+ PLWH in two populations of naïve B cells, two
310 populations of CD8+ T cells, and a population of resting NK cells. Both CXCR4 and ACTB play an
311 important role in the process of leukocyte transendothelial migration. CXCR4 activation is known to
312 drive both migration and proliferation of vascular cells. Leukocyte transendothelial migration involves
313 dynamic actin (ACTB) cytoskeleton remodeling, that is in part mediated by the key genes RHOA and
314 ROCK, which are not themselves differentially expressed between cells derived from AS+ and AS-
315 PLWH. However, gene sets related to this process were not significantly over-represented in the
316 differentially expressed genes for any subpopulations, with the exception of a small population of NK
317 resting cells.

318 The S100A8/S100A9 genes are upregulated in T cells CD8/NK resting cells (Figure 1C), monocytes
319 (Figure 1D), T cells CD8/CD4/CD4 naïve (Figure 1E) and B cells naïve – 2 cluster (Figure 1F) derived
320 from AS- PLWH. S100B is upregulated in CD8+ T cells populations derived from AS- subjects (Figure
321 1C, 1F). In monocytes, S100B has been shown to engage RAGE leading to overproduction of reactive
322 oxygen species, leading to the modulation of genes involved in inflammatory processes and adhesion to
323 vasculature (59). In addition, several ribosomal genes are upregulated in cells derived from AS- PLWH in

324 the B cells naïve –2 cluster (RPL8, RPS10, RPS26, RPS4Y1, RPS9), and upregulated in cells derived
325 from AS+ PLWH in the T cells CD8/CD4/CD4 naïve cluster (RP11-347P5.1, RPL13, RPL39, RPS14,
326 RPS27, RPS29, RPS6). The ribosome gene set was over-represented in the DE genes for 12 out of the 16
327 identified subpopulations (Supplementary Table 2). Ribosomal genes have been associated with cellular
328 states (60) and with the activity of the mTOR pathway (61-64).

329 While DE and enrichment analysis indicated some mechanisms of HIV-associated atherosclerosis, a
330 cohesive understanding of how these multiple genes (DE and non-DE) jointly regulate signaling cascades
331 did not emerge from the analysis above. Hence, we developed the network-based pathway analysis
332 algorithm scBONITA to further investigate the importance of specific genes and their role in signaling.

333 ***scBONITA algorithm for development of discrete-state models of*** 334 ***pathways***

335 To investigate dysregulated immune signaling, we used a discrete-state modeling approach to develop
336 executable models of signaling pathways. Specifically, we developed the scBONITA (Single-Cell
337 Boolean Omics Network Invariant-Time Analysis) algorithm using our previously established and
338 validated BONITA algorithm for scRNA-seq data (24) (Figure 2). Briefly, scBONITA uses a Boolean
339 framework where “AND” or “OR” logic gates are optimized to model signal integration and flow through
340 biological networks. scBONITA requires two inputs: (a) a binarized scRNA-seq dataset, and (b) a prior
341 knowledge network (PKN) (Figure 2A). PKNs describe pathway topology defined by nodes representing
342 genes and directed edges representing the activating or inhibitory interactions between nodes. The
343 optimized logic gates for a PKN are referred to as the rule set for that PKN. scBONITA leverages the
344 principle that observed states of single cells correspond to the steady states or attractors of dynamic
345 biological networks to identify regulatory rules for the input PKNs (Figure 2B). A genetic algorithm is
346 used to perform a global search and identify a minimum-error rule set which is further optimized by a
347 node-wise local-search. This procedure returns a set of discrete-state models for pathways referred to as

348 the equivalent rule set (ERS). A pathway is described in the text as ‘optimized’ if scBONITA-RD
349 successfully cuts down the state space of the possible rules for at least one node in the pathway.

350 The discrete-state models learned by scBONITA can be simulated to generate time-course trajectories
351 that are analogous to signal flow. They can also be perturbed *in silico* by simulation of gene knock-ins
352 and knockouts. We quantify the difference between network states after knock-out and knock-in, and
353 weight the score by the size of the ERS to quantify the uncertainty in rule determination for each node to
354 calculate a node-importance score that describes the influence of each node over the network. scBONITA
355 uses these node importance scores and comparison-specific fold changes from the scRNA-seq data used
356 for training to identify dysregulated pathways in a pre-specified contrast (Figure 2C). The simulation
357 trajectories of these discrete-state models fall into steady states known as attractors. These attractor states
358 of biological networks are the cell states with respect to specific pathways and have been hypothesized to
359 correspond to signaling behavior characteristic of specific cell types. Cells are assigned to the attractor
360 that is most similar to their expression data (Figure 2D). In this way, cells are matched to characteristic
361 signaling states for the network under consideration. Thus, scBONITA allows in depth investigation and
362 simulation of known biological signaling pathways by incorporating network topology.

363 ***scBONITA identifies dysregulated pathways in T cell populations in***
364 ***people living with HIV stratified by atherosclerosis***

365 The scBONITA pathway analysis algorithm identifies dysregulated pathways in all subpopulations
366 derived from AS+ and AS- PLWH, providing an insight into mechanisms of atherosclerosis development
367 in PLWH (Supplementary Table 3). ScBONITA optimized multiple pathways in CD8+ T cells that are
368 involved in this proinflammatory and anti-viral process (Figure 3A, Supplementary Table 3). These
369 pathways include the JAK-STAT signaling pathway, the TGF β signaling pathway, the NF κ B signaling
370 pathway, the AGE-RAGE signaling pathway, and the HIF-1 signaling pathway. In conjunction, cell-
371 migration pathways such as the regulation of actin cytoskeleton and axon guidance, the PI3K-AKT

372 signaling pathway and mTOR signaling pathway that modulate apoptosis and cell migration, are
373 identified as being dysregulated in the HIV+AS+ vs HIV+AS- contrast (Figure 3A). Only the Th17 cell
374 differentiation pathway was overall upregulated in cells derived from AS+ PLWH. All these pathways
375 were newly identified by scBONITA, i.e., the corresponding gene sets were not identified as being
376 enriched in the AS+/AS- contrast by enrichr (Supplementary Table 2).

377 Pathway analysis with scBONITA identified multiple optimized pathways in subpopulations containing
378 CD4+ T cells (T cells CD4 memory resting/T cells CD8, T cells naïve, and T cells CD4 -1 clusters,
379 Figure 1A) as being dysregulated (Bonferroni-adjusted p-value < 0.01) in the HIV+AS+ vs HIV+AS-
380 contrast (Figure 3B, Supplementary Table 3). CD4+ T cells may exert either an atherogenic or
381 atheroprotective phenotype, depending on subset and interactions with antigen presenting cells (APCs),
382 such as B cells in the adventitia or macrophages in plaques (65). Of the dysregulated pathways, herpes
383 simplex virus 1 infection and MAPK signaling pathways were overall upregulated in T cells CD4
384 memory resting/ T cells CD8 and T cells CD8/CD4/CD4 naïve cells derived from AS+ PLWH. The
385 proteoglycans in cancer and mTOR signaling pathways were overall upregulated in T cells CD4 memory
386 resting/ T cells CD8 from AS+ PLWH. PI3K-AKT signaling and chemokine signaling pathways were
387 upregulated in the T cells CD8/CD4/CD4 naïve cluster derived from AS+ PLWH. The ‘proteoglycans in
388 cancer’ signaling pathway is involved in cell adhesion and migration is upstream of processes known to
389 be dysregulated in atherosclerosis, such as regulation of the actin cytoskeleton, mTOR signaling, and
390 apoptosis. Similarly, the herpes simplex virus infection process involves activation of the PI3K-AKT
391 signaling and apoptosis pathways, which are known to be relevant in atherosclerosis.

392 The AGE-RAGE signaling pathway was further investigated in CD8+ T cells due to their relevance in
393 atherosclerosis and to demonstrate the additional information obtained from scBONITA in comparison to
394 other enrichment methods. The AGE-RAGE signaling pathway in a cluster of CD8+ T cells had the
395 highest pathway modulation score (0.8) amongst all tested pathways for this cluster (Supplementary Table
396 3). Most of the genes in this pathway were higher in AS+ PLWH (Figure 3C). Furthermore, the

397 uncertainty score was used to identify pathways where logic gates for genes could be optimized.
398 Particularly, scBONITA learned rules for the highly central DIAPH1 node, which has a high influence
399 over signal flow in this network due to its high connectivity (uncertainty score= 0.5) (Figure 3C). The
400 combination of scBONITA's node importance score and a difference in expression between the
401 HIV+AS+ and HIV+AS- groups was used to identify key genes which may or may not have a significant
402 difference in expression but whose activity influences the flow of signal through the network and the
403 signaling behavior in atherosclerosis. These key genes in AGE-RAGE pathway had higher expression in
404 AS+ PLWH. scBONITA assigns the class 1 PI3K genes (PIK3CA, PIK3CB and PIK3CD genes), the
405 P13K regulator PI3KR1, and PLC genes (PLCB1, PLCB2) maximal importance scores in this network.
406 All these genes are highly expressed in AS+ PLWH (Figure 3C). PI3K is known to activate intracellular
407 pathways involved in the pathophysiology of atherosclerosis, such as lipid accumulation and transport,
408 macrophage autophagy, phenotypic transition, and the expression of adhesion molecules involved in the
409 inflammatory response (reviewed in (66)). As noted in the preceding section, P13K is also downstream of
410 CXCR4, which is significantly upregulated in cells derived from AS+ PLWH. While CXCR4 is not itself
411 in this network topology, scBONITA nevertheless identifies its downstream effectors PI3K and PLC,
412 which are not themselves significantly differentially expressed, as playing an important role in the
413 signaling pathways leading to the expression of atherosclerosis-related genes and hence and
414 atherosclerotic phenotype. In this manner, pathway analysis with scBONITA revealed that several
415 pathways and genes associated with atherosclerosis are dysregulated in T cells derived from PLWH.
416 Many of these pathways have been previously shown to regulate T cell migration during atherosclerosis.

417 ***scBONITA identifies dysregulated pathways in monocytes in people***
418 ***living with HIV, stratified by atherosclerosis***

419 Pathway analysis with scBONITA identified multiple optimized dysregulated pathways in monocytes
420 (Figure 4A, Supplementary Table 3). Key pathways include the apoptosis, cAMP signaling, leukocyte

421 transendothelial migration, PI3K-AKT signaling and cellular senescence pathways, which appear to be
422 involved in the proinflammatory behavior of proatherogenic monocytes.(53, 67-76). Only the cAMP
423 signaling pathway and the endocrine resistance pathway are overall upregulated in cells derived from
424 AS+ PLWH.

425 The leukocyte transendothelial migration pathway was further investigated as monocyte migration outside
426 the vascular compartment plays a crucial role in the inflammatory cascade that leads to an atherosclerotic
427 phenotype (67, 69, 77). In addition, scBONITA was able to learn a limited set of regulatory rules for the
428 influential, highly connected RHOA gene (uncertainty factor=0.13). This pathway had a pathway
429 modulation score of 0.45, which is the third-highest pathway modulation score amongst tested pathways
430 for this cluster (Supplementary Table 3) (Figure 4B). scBONITA also assigned high importance scores to
431 the NCF genes (NCF1, NCF2, and NCF4), CYBA and CYBB. NCF genes are involved in superoxide
432 production and are a positive regulator of P13K signaling (78, 79). Once again, PLCG1 and PLCG2 are
433 assigned high importance scores by scBONITA in this network, underscoring the importance of PLC in
434 proinflammatory and proatherogenic processes. The upstream regulator of PLCG1, MSN, is involved in
435 cytoskeletal remodeling during leukocyte migration and is similarly assigned a high importance score
436 (80). ROCK2 shows only a small change across AS groups, which may be driven by feedback regulation
437 of mRNAs of ROCK genes but has a high importance score indicating a stronger role in regulating the
438 signal flow. The G protein GNAI3, which is downstream of CXCR4, is also assigned a high importance
439 score, possibly indicating a role for CXCR4-mediated activation of this pathway despite the low observed
440 fold change of CXCR4 between the AS+ and AS- groups. The downstream effectors of these high-
441 importance genes have higher fold changes than the high-importance genes themselves. These genes
442 include ACTG1 and EZR, which are involved in cytoskeletal remodeling (80-82), and ITGA4, ITGB1,
443 and ITGB2, which are involved in cell adhesion. As in the case of CD8+ T cells, pathway analysis with
444 scBONITA identifies several genes known to be associated with atherosclerosis which are also
445 dysregulated in monocytes derived from PLWH.

446 ***Pathways dysregulated by HIV infection are implicated in***
447 ***atherosclerosis***

448 To identify the biological mechanisms modulated by HIV infection we analyzed PBMCs from four
449 individuals before and during acute HIV infection. Specifically, Kazer et al (36) sequenced PBMCs from
450 4 individuals before and during acute HIV infection and identified gene expression programs activated in
451 proinflammatory T cells, monocytes, and NK cells during HIV infection. Pre-clustered scRNA-seq data
452 and the set of KEGG networks used in the above analysis were used with scBONITA to infer Boolean
453 rules and perform pathway analysis. We compared pathways that were dysregulated pathways after 1 year
454 of HIV infection (36) to those identified as being dysregulated ($p_{adj} < 0.1$) in the AS+HIV+ vs AS-
455 HIV+ contrast from our dataset described above (Figure 6A). Subpopulations of immune cells in the two
456 datasets were matched for the purpose of this comparison as shown in Supplementary Table 6, except for
457 dendritic cells, which did not have a matching subpopulation in the HIV/AS dataset.

458 scBONITA identified 10 optimized pathways that were dysregulated after 1 year of HIV infection in
459 cytotoxic T cells (36) (Figure 3A-B, Figure 6A, Supplementary File 1, Supplementary Figure 5,
460 Supplementary Table 5, Supplementary Table 6). Of these pathways, the 'Axon guidance', 'MAPK
461 signaling', 'Proteoglycans in cancer', 'Herpes simplex virus 1 infection', and 'Cytokine-cytokine receptor
462 interaction' signaling pathways were also dysregulated in PLWH with AS. Similarly, 5 out of 19
463 optimized pathways were dysregulated in monocytes upon HIV infection and in AS+ individuals (Figure
464 4A, Figure 6A, Supplementary File 1, Supplementary Figure 5, Supplementary Table 6). The herpes
465 simplex virus 1 infection, PI3K-AKT signaling, and cellular senescence pathways were dysregulated
466 upon HIV infection and in PLWH with AS. While overall dysregulation of the pathways is a crude metric
467 for activation, we note that 81 and 41 genes from these overlapping pathways were upregulated in both
468 contrasts in the cytotoxic T cell populations and monocyte population respectively (Figure 6B and 6C,
469 statistical significance was not tested). Enrichment analysis using KEGG biological pathways suggests
470 that the genes upregulated after HIV infection and in AS+ PLWH in the CD8+ T cell subpopulation were

471 enriched for viral response pathways such as herpes simplex virus 1 infection and human cytomegalovirus
472 infection (Supplementary File 1, Supplementary Figure 6). Similarly, the genes upregulated after HIV
473 infection and in AS+ PLWH in the monocyte subpopulation were enriched for cell migration related
474 pathways such as the PI3K-AKT signaling pathway and the cAMP signaling pathway (Supplementary
475 File 1, Supplementary Figure 6). In this vein, mTOR signaling was dysregulated in T cells from both
476 datasets and proteoglycans in cancer, PI3K-AKT signaling, and cellular senescence were dysregulated in
477 B cells from both datasets. These dysregulated pathways suggest that the modulation of cell migration and
478 inflammation processes upon HIV infection progresses over time, leading to AS in PLWH.

479 ***Attractor analysis reveals PI3K genes driving distinct cellular***
480 ***signaling states potentially associated with atherosclerosis***

481 We performed attractor analysis for the pathways significantly dysregulated between AS+ and AS-
482 PLWH in the cluster of CD8+ T cells discussed above (Cluster CD8 T cells -1 in Figure 1A). The
483 attractor analysis facilitates evaluation of cellular states across subjects and disease groups. The simplest
484 rules, which have the smallest number of “AND” terms, were chosen to simulate the network and identify
485 attractors as described in the Methods. The insulin resistance pathway, which is downstream of the AGE-
486 RAGE signaling and the PI3K-AKT pathways, was particularly interesting because more than 50% of the
487 same cluster of CD8+ T cells mapped to three dominant attractors. scBONITA identified 72 attractors
488 representing cellular states with respect to the insulin resistance pathway in CD8+ T cells. Of these 72
489 signaling states, 3 dominant signaling states mapped to 16.5%, 7.5% and 27.4% of cells respectively
490 (Figure 5A-B). The insulin resistance pathway was found to have a significant association between
491 identified attractors and subjects (chi-square test, p-value < 0.05) but no significant association between
492 identified attractors and atherosclerosis status (chi-square test, p-value > 0.05). Notably, attractor analysis
493 showed that there was significant association between assigned attractors and subject from which cells
494 were derived for the T cells CD4 - 1 and T cells CD8/CD4/CD4 naïve clusters for the chemokine signaling

495 pathway (chi-square test, $p < 0.01$). The attractors of the PI3K-AKT signaling pathway were significantly
496 associated with subject for the T cells CD8/CD4/CD4 naive cluster (chi-square test, $p < 0.01$).

497 These cellular states were characterized by differences in several key genes (Figure 5C), including PI3K
498 genes (PI3KA, B, and D) and the PI3K regulators (PIK3R1, 2, and 3) that were identified as being highly
499 influential in the AGE-RAGE signaling pathway (Figure 3B). In addition, the two less abundant attractors
500 differed in the activity of the key TNFR and TNF genes. Hence, these attractors are referred to as the
501 PIK3R+ PIK3+, TNFR+TNF- and TNFR-TNF+ attractors. The activity of these PI3K genes and the
502 activity of AKT genes (AKT1, 2 and 3) was higher in the most common signaling state (PI3KR+ PI3K+
503 attractor). However, the activity of the downstream targets of AKT, such as CREB1, CREB3, CREB5,
504 NFKB1, FOXO1, CREB3L4 and CREB3L42 were lower in the PI3KR+ PI3K+ attractor. TNF, which is
505 known to be produced at a low level by some subsets of T cells, also mediates a range of pro-
506 inflammatory processes in vascular endothelial cells, particularly leukocyte adhesion and transendothelial
507 migration (83, 84). TNF-TNFR1 signaling mediates an apoptotic process that is mediated by TRADD and
508 FADD (85). In addition, TNFR1 is known to activate the PI3K signaling pathway in regulatory T cells in
509 the context of autoimmune disease (86). These differences may indicate differences in TNF production
510 and response in the cells that are assigned to these cell states. Significant differences in signaling modes
511 of cells exist across subjects, suggesting the existence of distinct modes of operation (Figure 5D).

512 Attractor analysis of the leukocyte transendothelial migration pathway in monocytes revealed 9 attractors
513 that mapped to cells in the dataset and two dominant signaling modes mapping to 51.04% and 30.73 % of
514 cells respectively (Figure 6A-B). The two dominant signaling modes of this pathway in monocytes
515 differed in the activity of the PECAM1 and F11R genes (Figure 6C) and are hence referred to as the
516 PECAM+ and F11R+ attractors. F11R is required for platelet adhesion to vascular endothelial cells (87),
517 which occurs prior to infiltration of monocytes into the endothelium and eventual plaque formation (88,
518 89). PECAM1 has been recognized as an influential signaling molecule with widespread effects on
519 vascular biology and atherosclerosis in particular (90-92). Attractors for this pathway were significantly

520 associated with the subjects (chi-square test, p-value < 0.05, Figure 6 B), but were not significantly
521 associated with atherosclerosis status (chi-square test, p-value > 0.05). Similarly, the attractor activity of
522 individual genes was not significantly associated with atherosclerosis status (t-test, p-value > 0.05).
523 However, we observed significant variation in attractor activity for PECAM1 and F11R across subjects,
524 reflective of the different states of the cells across subjects. Thus, scBONITA allows us to investigate
525 cellular states potentially associated with inter-subject variability, driven by molecular signaling.

526 ***Evaluation of scBONITA performance in silico***

527 The BONITA algorithm has already been rigorously validated in our previous study (24). Specifically,
528 comparison with other network-based pathway analysis tools has been performed. Here we evaluate
529 scRNA-seq specific components of the algorithm. To show that scBONITA rule determination is robust
530 to training set size, we varied the size of the training data provided to scBONITA. Specifically, the
531 number of cells in the largest cluster of cells (Naïve B cells -1) were varied by random selection from 1%
532 of cells from that cluster to 200% by adding cells from neighboring clusters. The reduced size of the ERS
533 for nodes with in-degree 3 (i.e., the most complex case considered by scBONITA) informs improved
534 certainty in rule inference by scBONITA. (Figure 7A) While there was a significant decline in
535 performance when the data was downsampled to 1% of the original cluster, there was no significant
536 increase in effect once 50% of the cells were used, or when the training dataset was augmented. This
537 indicates that scBONITA is robust to heterogeneity in the training data set. To show that scBONITA's
538 node importance score is not correlated to commonly used measures of node centrality, we compared the
539 node importance scores calculated by scBONITA for KEGG networks when it is trained on the HIV/AS
540 dataset as described above to six centrality measures – Katz centrality, degree centrality, current flow
541 centrality, eccentricity centrality, betweenness centrality, and local reaching centrality. We observed that
542 scBONITA's node importance score is not correlated to any of these metrics (Spearman Correlation
543 Coefficient < 0.15, Figure 6H). To show that network topology also significantly influences the node
544 importance score, we compared scBONITA's node importance scores for the same set of KEGG

545 pathways, assigned using different training datasets. These node importance scores were compared using
546 similar cell subpopulations only. We found that the node importance scores between the two datasets
547 were correlated as shown by a representative comparison between the node importance scores for the
548 subpopulation of cytotoxic T cells from the Kazer et al dataset and the subpopulations of CD8+ T cells
549 (Figure 6B, $0.71 < \text{Pearson Correlation Coefficient} < 0.91$, $p < 0.01$) show. Similarly, the node
550 importance scores for the populations of monocytes were highly correlated (Pearson correlation
551 coefficient = 0.78, Supplementary Table 4, Supplementary File 1, Supplementary Figure 3). However, the
552 correlations were relatively lower for other pairs of subpopulations (Supplementary Table 4,
553 Supplementary File 1, Supplementary Figure 5), indicating that scBONITA learns some characteristic
554 features of a network topology, but node importance scores are still assigned in a context-dependent
555 manner.

556 Discussion

557 Among people living with HIV, widespread use of cART has significantly reduced overall mortality.
558 However, the earlier and increased incidence of cardiovascular diseases, including atherosclerosis,
559 remains the major cause of mortality in an aging HIV+ population. The causes for this are manifold and
560 include side effects of cART and lower level of HIV proliferation (4, 9-12). We and others have
561 attempted to identify the immune signaling mechanisms that lead to this increased incidence of
562 atherosclerosis (93). However, to the best of our knowledge no study has attempted to holistically study
563 the combined effects of variance in the numbers of specific immune cells and the cell-type specific
564 signaling dysregulations (93). We found that in accordance with previous studies (19, 94-100), a
565 population of CD8+ T cells was significantly increased in PBMCs from AS+ PLWH. However, contrary
566 to our expectations (20, 68, 69, 74, 76, 101-104), a population of monocytes was significantly *decreased*
567 in PBMCs from AS+ PLWH. Interestingly, evaluation by our pathway analysis algorithm scBONITA and
568 differential expression analysis identified differences in the migratory phenotype of these cells,
569 suggesting to us that these monocytes are migrating into the vascular intima in AS+ PLWH (described

570 later in the discussion). Conventional differential expression and gene set enrichment analysis methods
571 identified genes involved in signaling pathways that are known to be linked to cell migration and cell
572 aging. Key amongst these identified genes were CXCR4 and ACTB (Figure 1 C-F) which were
573 upregulated in populations of CD8+ T cells derived from AS+ PLWH. CXCR4 activation by its ligands
574 leads to the activation of phosphatidylinositol-3-OH kinases (PI3K), which in turn leads to the activation
575 of the serine-threonine kinase AKT via PIP3 (105). PI3K/AKT signaling leads to multiple processes
576 involved in plaque formation, such as cell migration, intracellular lipid accumulation, and smooth muscle
577 cell proliferation (66). S100A8/S100A9 were found to be upregulated in monocytes derived from AS-
578 PLWH (Figure 1 C-F). In monocytes, S100A8/9 have been shown to increase adhesion, migration, and
579 production of inflammatory cytokines such as TNF-alpha and IL1 β (106, 107). However, none of these
580 processes were identified as being significantly enriched in the differentially expressed genes from these
581 subpopulations. In addition, these methods failed to provide insights into how disparate genes involved in
582 different pathways regulate cellular states. To characterize signaling dysregulations in HIV-associated
583 atherosclerosis more effectively, we developed the scBONITA algorithms for regulatory rule inference,
584 network simulation, pathway analysis, and attractor/steady-state analysis.

585 scBONITA learns condition-specific logic models using scRNA-seq data in conjunction with published
586 prior knowledge networks. This study builds on our previously published BONITA method (24) that
587 inferred logic rules from bulk RNAseq data. scBONITA exploits the bimodal nature of scRNA-seq data
588 (38, 108) and the cell-level resolution of expression to successfully learn regulatory rules and identify
589 attractors for prior knowledge networks. We show that scBONITA can successfully learn regulatory rules
590 for biologically significant signaling pathways and that these rules can be used to perturb and simulate
591 these pathways *in silico*. Unlike other tools utilizing Boolean networks, scBONITA is not dependent on
592 time-series data and in fact hypothesizes that scRNA-seq data represents samples in the state space of a
593 dynamic Boolean network. In addition, scBONITA uses published network topologies, thereby reducing
594 the uncertainty in the inferred rules. Other groups have published algorithms to infer logic rules and

595 reconstruct gene-regulatory networks on a small subset of genes from scRNA-seq data (51, 109, 110).
596 However, scBONITA does not depend on pre-selection of genes. Additionally, scBONITA also identifies
597 dysregulated signaling pathways in a given context, combining expression information with scBONITA
598 derived impact score to create a unique metric of pathway dysregulation that considers (a) the dynamic
599 nature of signaling pathways and (b) the impact of node perturbations.

600 scBONITA identifies interesting, dysregulated pathways across all cell subpopulations in the HIV/AS
601 dataset (Supplementary Table 3, Figures 3-4). The AGE-RAGE signaling pathway was significantly
602 dysregulated in a population of CD8+ T cells (Figure 3A). AGE-RAGE signaling elicits activation of
603 multiple intracellular signaling pathways such as cell proliferation and apoptosis pathways (111-119).
604 scBONITA assigned the highest importance scores for this network to the PI3K family of genes
605 (PIK3CA, PIK3CB and PIK3CD), which promote intracellular lipid deposition leading to the formation
606 of foam cells and atherosclerotic plaques and can also reduce the expression of lipid transporters and
607 reduce the efflux of intracellular cholesterol depending on upstream signals (66). PLC (PLCB1 and
608 PLCB2 genes), which is also assigned a high importance score in this network, facilitates
609 proinflammatory and proatherogenic processes. PLC activity induced by oxidized low-density lipids
610 (oxLDL) serves to stimulate proinflammatory IL-8 secretion and promote leukocyte adhesion, promoting
611 plaque development. PLC also enhances endothelial dysfunction and plaque progression by inducing
612 VEC apoptosis (80, 120). Of note, both PI3K and PLC genes were upregulated in AS+ PLWH (Figure
613 3C).

614 ScBONITA identified several pathways linked to lipid metabolism as being dysregulated in the
615 population of monocytes. Amongst these pathways were the cAMP signaling pathway, which was overall
616 upregulated in AS+ PLWH, and leukocyte transendothelial migration pathway, which was overall
617 upregulated in AS- PLWH, both of which are involved in the infiltration of monocytes into the intima
618 during the formation of atherosclerotic lesions and hence progression of atherosclerosis (52-57).
619 Similarly, scBONITA identified genes critical to the atherosclerotic process in the leukocyte

620 transendothelial migration pathway trained on the monocyte subpopulation. Specifically, ROCK1 and
621 ROCK2 are stimulated by atherogenic stimuli, such as oxLDL. ROCK activation leads to various
622 pathophysiological changes include endothelial dysfunction, migration and angiogenesis, migration,
623 proliferation and differentiation in SMCs and vascular remodeling (121, 122). ROCK inhibitors such as
624 statins have been recently shown to attenuate atherosclerosis by inhibiting ROCK1 and ROCK2 and
625 consequently inhibition of altered chemotaxis of macrophages and its transformation into foam cells
626 (123). The dysregulation of the glucagon signaling pathway, cAMP signaling, PI3K-AKT signaling and
627 proteoglycans in cancer pathways indicate that in AS+ PLWH, dysregulations in glucose metabolism
628 induce expression of adhesion molecules by the vascular endothelium resulting in increased monocyte
629 transendothelial migration (66, 124). In this manner, scBONITA revealed novel insights into pathway
630 regulation upon atherosclerosis.

631 Pathway analysis with scBONITA shows that lipid metabolism and cell migration are dysregulated in
632 AS+ PLWH across all cell subpopulations. This effect is most clearly seen in the case of the PI3K-AKT
633 signaling pathway, which is dysregulated in all cell subpopulations (Figures 4 – 5, Supplementary Table
634 3). The pathways that are upstream and downstream of PI3K-AKT signaling are, however, dysregulated
635 in different subpopulations, suggesting that the activation and effector mechanisms of this signaling
636 cascade vary by cell type. While there appears to be no strong evidence for apelin expression in B cells,
637 the apelin signaling pathway was upregulated in B cells naïve -1 derived from AS+ PLWH and
638 adipocytokine signaling pathway was downregulated in B cells naïve -2 derived from AS+ PLWH, along
639 with PI3K-AKT signaling and MAPK signaling. The cardioprotective effect of apelin is modulated by
640 (amongst other routes) the PI3K-AKT signaling and MAPK signaling pathways (80-82). It is also shown
641 to be upregulated in human atherosclerotic coronary arteries and colocalized with markers for
642 macrophages (125, 126). PI3K-AKT signaling is also dysregulated in CD4+ T cells (Figure 4B), as is its
643 upstream signaling pathway cytokine-cytokine receptor interaction, suggesting a different mechanism of
644 activation of PI3K-AKT signaling in this cell type.

645 We used the scBONITA pipeline to infer pathways involved in the progression of HIV infection from an
646 independent, publicly available scRNA-seq dataset derived from 4 subjects before and after HIV infection
647 and compared these pathways to those identified in the progression of atherosclerosis in PLWH.
648 scBONITA-RD was able to successfully learn regulatory rules for KEGG pathways when trained on this
649 dataset (Supplementary File 1, Supplementary Figure 4). Several pathways dysregulated upon HIV
650 infection were also dysregulated in PLWH with AS (Figure 3A, Figure 4A, Supplementary File 1,
651 Supplementary Figure 5, Supplementary Table 6). Among the dysregulated pathways, the proteoglycans
652 in cancer pathway, which is linked to cell migration and adhesion, and the axon guidance pathway, which
653 is linked to cytoskeletal reorganization and Rho GTPase signaling and has been suggested to be a special
654 case of cell migration that is active in many cell types, are both also suggestive of changes occurring in
655 cell migration of cytotoxic T cells due to HIV infection (127-130). Interestingly, both these pathways are
656 also linked to the cytokine - cytokine receptor interaction pathway. cAMP signaling negatively regulates
657 the production of PI3K-AKT signaling and hence the transcription of pro-inflammatory cytokines via
658 PKA, and positively regulates the transcription of anti-inflammatory cytokines via PKA and CREB.
659 Decreased PI3K-AKT signaling results in decreased cell migration (131). The PI3K-AKT signaling,
660 cAMP signaling, and cellular senescence pathways were dysregulated in the population of monocytes
661 derived after one year of HIV infection and in monocytes derived from PLWH with AS, further indicating
662 an HIV-induced dysregulation in cell migration processes. These conclusions were further borne out by
663 the enrichment analysis of genes from these pathways that were upregulated after HIV infection and in
664 atherosclerosis (Figure 7).

665 To map cells to distinct signaling modes of the pathways described above, we developed scBONITA's
666 attractor analysis capabilities. Attractors are regions in the state space of a dynamic system towards which
667 simulation trajectories are "pulled" or attracted. These attractors and the propensity of simulation
668 trajectories to end in these attractors (i.e., the size of the attractor basins) are characteristics of a specific
669 network with a specific set of regulatory rules. Previous works have suggested that these steady states

670 correspond to observable cell states, or hallmarks of specific phenotypes such as cell type differentiation,
671 disease state, or drug treatment (132-137). These studies show that even simple dynamic models capture
672 rich and nuanced cell behaviors. ScRNA-seq allows the study of these dynamic landscapes and their
673 steady states or attractors at an unprecedented resolution (137-139). scBONITA uses learned rules to map
674 cells to characteristic signaling states based on the property of Boolean networks to move towards steady
675 states or attractors. This attractor analysis allows users to characterize cells based on the dynamic
676 properties of signaling networks, which dictate their phenotype. scBONITA not only identifies these
677 attractors, but it also allows identification, of the master regulators or switches that control the changes
678 between these cell states by evaluating scBONITA's node importance score. Thus, this attractor analysis
679 provides complex insights into cellular processes in a variety of conditions.

680 The importance of cell migration and dysregulated lipid signaling in the development of HIV-associated
681 atherosclerosis was further underscored by attractor analysis with scBONITA. We identified attractors for
682 all signaling pathways that were identified as being dysregulated upon AS in PLWH in CD8+ T cells and
683 monocytes, and mapped cells to these identified signaling states. Furthermore, we identified signaling
684 pathways in which (a) more than one attractor mapped to a significant proportion of cells from the cluster
685 under consideration and (b) there was a significant association between the attractor to which cells were
686 assigned and the subject from which these cells were derived. We note that in most cases, multiple
687 theoretically possibly signaling modes (attractors) were identified but only one dominant signaling state
688 existed in the dataset. Using the criteria defined above, we selected the insulin resistance pathway in
689 CD8+ T cells and the leukocyte transendothelial migration pathway in monocytes for further analysis
690 (140-144). We also note that the insulin signaling pathway exerts immunomodulatory effects on T cells.
691 Decreased insulin receptor expression (used as a proxy for insulin resistance) during viral infection has
692 been shown to downregulate components of the infection response, such as proliferation, cytokine
693 response and glycolysis (140). The three dominant signaling modes of the insulin resistance pathway
694 differed in the activity of PI3K and AKT genes, which were identified as key regulators of the pathways

695 described in the preceding sections, and their downstream effectors, such as CREB and FOXO1. This
696 suggests the existence of two distinct modes of operation for this signaling pathway corresponding to a
697 proliferative cell state (activation of PI3K and AKT) and a senescent cell state (transcription of CREB-
698 and FOXO1-controlled genes) (141, 142, 145). Similarly, we identified two dominant signaling modes for
699 the leukocyte transendothelial migration pathway in monocytes. These modes differed in the activity of
700 F11R and PECAM1 genes, which were active in the most common and second most common attractor
701 respectively. While there is no significant separation between cells derived from AS+ and AS- PLWH
702 based on the attractors that they map to, the existence of these two signaling modes suggests variation in
703 the cell states with respect to this pathway in PLWH. Dysregulation in insulin signaling promotes
704 PECAM1-mediated migration of monocytes through endothelial cells (146, 147). Emerging evidence
705 suggests that PECAM1's loss contributes to atherosclerosis (92). The presence of a signaling state in
706 which PECAM1 is deficient may therefore indicate that those cells are contributing to a negative
707 feedback loop of the inflammatory process. The identification of pathway-specific signaling modes that
708 can be differentiated based on specific gene activities shows that scBONITA can shed light on signaling
709 mechanisms that are not apparent by analysis of gene expression differences alone.

710 Although BONITA algorithm has been rigorously validated in our prior publication (46) here we wanted
711 to evaluate the scRNA-seq data specific parts of the algorithm. We next assessed whether the provided
712 network topology also significantly influences the node importance score, and the dependence of the node
713 importance score on the training data. We demonstrated the influence of network topology on the node
714 importance score (Figure 7B), which is also an indirect measure of the similarity (though not identity) of
715 the rules inferred by scBONITA for a given network, using different datasets. Thus, scBONITA can
716 identify characteristic structural properties of networks and use this in conjunction with expression
717 information to identify dysregulated pathways in a specified condition. We also show that scBONITA's
718 node importance score is not correlated with measures of node centrality (Figure 6H). We also assessed
719 the dependence of scBONITA on the training data to show that scBONITA-RD can narrow down the vast

720 possible state space for a Boolean network (Figure 6A). This ability is dependent on the similarity of the
721 signaling process operating in the cells of the training dataset. scBONITA's ability to resolve rules
722 decreases slightly when the heterogeneity of the training dataset increases (Figure 7E, 200% cells). This
723 restricts the ability of scBONITA to identify regulatory rules that can be experimentally verified. We
724 expect that this capability will improve significantly when pure cell populations are sequenced, for
725 example after flow cytometry or pure cell culture. While scBONITA is not strictly dependent on the
726 clustering method used to classify scRNA-seq data into subpopulations, we used pre-classified
727 subpopulations to reduce variability and, additionally, to improve the specificity of scBONITA-PA by
728 restricting the identification of dysregulated pathways to cell types. This is consistent with the typical
729 gene set enrichment analysis in the context of scRNA-seq data. Additionally, scBONITA-RD requires a
730 longer runtime (<12 hours in our tests) and more powerful computational capabilities than a typical
731 analysis pipeline run on scRNA-seq dataset of typical size; however, these resources are usually available
732 to academic users on computing clusters.

733 The biological variability and nonspecific distortions of expression due to the technicalities of scRNA-seq
734 has been previously identified (148), leading to identification of fewer differences across conditions, as in
735 studies such as (149). In addition, even differential expression methods that are sensitive to the known
736 characteristic distributions of scRNA-seq data are prone to false discoveries (recently reviewed in
737 34584091). Our approach implemented in scBONITA allows analysis of genes in the context of their
738 function in the signaling pathways and network topology of the interactions. This additional information
739 minimizes the impact of the caveats in the scRNA-seq technology mentioned above. Thus, our analysis
740 reveals influential genes in several signaling networks in a context-specific manner, thereby predicting
741 novel targets for further experimental validation or for therapies.

742 **Conclusions**

743 To study the cellular and immunological processes involved in HIV-associated atherosclerosis, we used
744 scRNA-seq to profile PBMCs from 8 PLWH, 4 of whom had atherosclerosis. We developed the
745 scBONITA algorithm to use this scRNA-seq data to (a) infer regulatory rules for networks with a known
746 topology, (b) perturb and simulate these networks *in silico* to identify master regulators of these networks,
747 (c) combined this topology-specific information with expression information to identify dysregulated
748 pathways in this condition, and (d) grouped cells into characteristic signaling states based on the dynamic
749 properties of these networks. We validated scBONITA on a publicly available dataset of PBMCs from
750 persons before and after HIV infection. scBONITA identified key dysregulated pathways that drive
751 inflammation in people living with HIV. The scBONITA source code, along with documentation and
752 tutorials, is freely available on <https://github.com/Thakar-Lab/scBONITA>.

753 **List of abbreviations**

754 AS: atherosclerosis; HIV: human immunodeficiency virus; PLWH: people living with HIV; PBMC:
755 peripheral blood mononuclear cell; scBONITA: single-cell Boolean Omics Network Invariant Time
756 Analysis; single-cell RNA sequencing: scRNA-seq; CVD: cardiovascular disease; ORA:
757 overrepresentation analysis; cART: combined antiretroviral therapy; KEGG: Kyoto Encyclopedia of
758 Genes and Genomes; scBONITA-RD: single-cell Boolean Omics Network Invariant Time Analysis rule
759 determination; scBONITA-PA: single-cell Boolean Omics Network Invariant Time Analysis pathway
760 analysis; GA: genetic algorithm; LS: local search; RA: relative abundance; ERS: equivalent rule set;
761 PKN: prior knowledge network

762 **Acknowledgements**

763 We would like to thank Adam Cornwell, Jiayue Meng and George Kassis for testing scBONITA at
764 various stages of development and for useful discussions on scBONITA functionality. We would also like

765 to thank Alan Grossfield, Andrew McDavid, Gourab Ghoshal, David Mathews, Lauren Benoodt, Raven
766 M. Osborn, and all past and present members of the Thakar Lab for helpful discussions. The Center for
767 Integrated Research Computing at the University of Rochester provided high-performance computing
768 resources and computing expertise. We are especially grateful to the participants in the HIV/AS study,
769 their families, and the clinical team.

770 **Funding**

771 The study was supported by U.S. National Institutes of Health. MGP is supported by R01 AI134058. RP
772 is supported by T32 GM07356. JT was supported by UM1 AI069511, P30 AI078498, R01 AI134058 and
773 R21 AI136668. SBM, GS and AT were supported by R01 HL123346, SBM and MVS are supported by
774 R01 HL128155, R01 NS066801. The University of Rochester Center for AIDS Research (UR-CFAR;
775 P30 AI078498) provided support and core facilities.

776 **Declarations**

777 ***Authors' information***

778 **Affiliations**

779 ¹Biophysics, Structural, and Computational Biology Program, University of Rochester School of
780 Medicine and Dentistry, Rochester, USA. ² Medical Scientist Training Program, University of Rochester
781 School of Medicine and Dentistry, Rochester, USA. ³University of Rochester Clinical & Translational
782 Science Institute. ⁴Department of Microbiology, Immunology and Tropical Medicine, George
783 Washington University School of Medicine and Health Sciences, Washington, D.C., USA. ⁵Department
784 of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, USA. ⁶Department
785 of Imaging Sciences, University of Rochester School of Medicine and Dentistry, Rochester, USA.
786 ⁷Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and

787 Dentistry, Rochester, USA. ⁸Department of Microbiology and Immunology, University of Rochester
788 School of Medicine and Dentistry, Rochester, USA. ⁹Department of Biomedical Genetics, University of
789 Rochester School of Medicine and Dentistry, Rochester, USA

790 **Authors' contributions**

791 Conceptualization of the study: JT, conceptualization of BONITA: MGP, RP, JT; Data curation: MGP,
792 AT, JT; Formal Analysis: MGP, JT; Funding acquisition: SM, GS, JT; Investigation: MGP, JT;
793 Methodology: MGP, JT; Project administration: AT, JT; Resources: SM, GS, MVS, JT; Software: MGP,
794 JT; Supervision: JT; Validation: MGP, JT; Visualization: MGP, JT; Writing – original draft: MGP, JT;
795 Writing – review & editing: All authors

796 ***Ethics Declarations***

797 **Ethics approval and consent to participate**

798 All methods were carried out in accordance with University of Rochester guidelines and regulations, and
799 all experimental and study protocols were approved by the University of Rochester Institutional Review
800 Board (#RSRB00063845). All study participants gave their written informed consent.

801 **Consent for publication**

802 Not applicable

803 **Availability of data and materials**

804 The HIV/AS scRNA-seq dataset presented in this manuscript has been deposited in Single Cell Portal and
805 will be made public upon publication of the manuscript. Due to the sensitive nature of HIV data, we have
806 not made the raw data public; however, all results presented in this manuscript may be recapitulated from
807 the data in Single Cell Portal. We also analyzed a previously published dataset that is freely accessible at

808 https://singlecell.broadinstitute.org/single_cell/study/SCP256. All source code and documentation for the
809 scBONITA package is available at <https://github.com/Thakar-Lab/scBONITA>.

810 **Competing interests**

811 The authors declare that they have no competing interests.

812 **References**

- 813 1. McLaughlin MM, Ma Y, Scherzer R, Rahalkar S, Martin JN, Mills C, et al. Association of Viral
814 Persistence and Atherosclerosis in Adults With Treated HIV Infection. *JAMA Netw Open*.
815 2020;3(10):e2018099.
- 816 2. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of
817 Atherosclerotic Cardiovascular Disease in People Living With HIV. *Circulation*. 2018;138(11):1100-12.
- 818 3. Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison
819 of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining
820 cancer in HIV-infected versus uninfected adults. *Clin Infect Dis*. 2015;60(4):627-38.
- 821 4. Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, et al. Increased Risk of
822 Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General
823 Population. *J Acquir Immune Defic Syndr*. 2017;75(5):568-76.
- 824 5. Mdofo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT, et al. Cigarette smoking
825 prevalence among adults with HIV compared with the general adult population in the United States:
826 cross-sectional surveys. *Ann Intern Med*. 2015;162(5):335-44.
- 827 6. Tien PC, Schneider MF, Cox C, Karim R, Cohen M, Sharma A, et al. Association of HIV
828 infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. *J*
829 *Acquir Immune Defic Syndr*. 2012;61(3):334-40.
- 830 7. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-
831 sectional comparison of the prevalence of age-associated comorbidities and their risk factors between
832 HIV-infected and uninfected individuals: the AGEHIV cohort study. *Clin Infect Dis*. 2014;59(12):1787-
833 97.
- 834 8. Cotter AG, Satchell CS, O'Halloran J A, Feeney ER, Sabin CA, Mallon PW. High-density
835 lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients. *Aids*. 2011;25(6):867-9.
- 836 9. Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-Infected Adults: Novel
837 Pathophysiologic Mechanisms. *Hypertension*. 2018;72(1):44-55.
- 838 10. Hatleberg CI, Ryom L, d'Arminio Monforte A, Fontas E, Reiss P, Kirk O, et al. Association
839 between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the
840 Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *HIV Med*. 2018;19(9):605-18.
- 841 11. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and
842 cardiovascular risk factors among patients with human immunodeficiency virus disease. *J Clin*
843 *Endocrinol Metab*. 2007;92(7):2506-12.
- 844 12. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection
845 and the risk of acute myocardial infarction. *JAMA Intern Med*. 2013;173(8):614-22.
- 846 13. Vos AG, Idris NS, Barth RE, Klipstein-Grobusch K, Grobbee DE. Pro-Inflammatory Markers in
847 Relation to Cardiovascular Disease in HIV Infection. A Systematic Review. *PLoS One*.
848 2016;11(1):e0147484.

- 849 14. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial
850 inflammation in patients with HIV. *Jama*. 2012;308(4):379-86.
- 851 15. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. Soluble CD163
852 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to
853 and after anti-retroviral therapy. *The Journal of infectious diseases*. 2011;204(1):154-63.
- 854 16. Dirajlal-Fargo S, Sattar A, Kulkarni M, Funderburg N, McComsey GA. Soluble TWEAK may
855 predict carotid atherosclerosis in treated HIV infection. *HIV Clin Trials*. 2017;18(4):156-63.
- 856 17. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in
857 HIV-1 infection. *Blood*. 2011;117(21):5582-90.
- 858 18. Longenecker CT, Sullivan C, Baker JV. Immune activation and cardiovascular disease in chronic
859 HIV infection. *Curr Opin HIV AIDS*. 2016;11(2):216-25.
- 860 19. Schäfer S, Zerneck A. CD8(+) T Cells in Atherosclerosis. *Cells*. 2020;10(1):37.
- 861 20. Jaworowski A, Hearps AC, Angelovich TA, Hoy JF. How Monocytes Contribute to Increased
862 Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination
863 Antiretroviral Therapy. *Front Immunol*. 2019;10:1378.
- 864 21. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding
865 challenges. *PLoS computational biology*. 2012;8(2):e1002375-e.
- 866 22. Thakar J, Pilione M, Kirimanjeshwara G, Harvill ET, Albert R. Modeling systems-level regulation
867 of host immune responses. *PLoS Comput Biol*. 2007;3(6):e109.
- 868 23. Van Twisk D, Murphy SP, Thakar J. Optimized logic rules reveal interferon-gamma-induced
869 modes regulated by histone deacetylases and protein tyrosine phosphatases. *Immunology*.
870 2017;151(1):71-80.
- 871 24. Palli R, Palshikar MG, Thakar J. Executable pathway analysis using ensemble discrete-state
872 modeling for large-scale data. *PLoS Comput Biol*. 2019;15(9):e1007317.
- 873 25. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. *Nature reviews*
874 *Cardiology*. 2020;17(7):387-401.
- 875 26. Tay C, Kanellakis P, Hosseini H, Cao A, Toh B-H, Bobik A, et al. B Cell and CD4 T Cell
876 Interactions Promote Development of Atherosclerosis. *Frontiers in Immunology*. 2020;10.
- 877 27. Tse K, Tse H, Sidney J, Sette A, Ley K. T cells in atherosclerosis. *Int Immunol*. 2013;25(11):615-
878 22.
- 879 28. Abdolmaleki F, Gheibi Hayat SM, Bianconi V, Johnston TP, Sahebkar A. Atherosclerosis and
880 immunity: A perspective. *Trends Cardiovasc Med*. 2019;29(6):363-71.
- 881 29. Perry H, Bender T, McNamara C. B cell subsets in atherosclerosis. *Frontiers in Immunology*.
882 2012;3.
- 883 30. Srikakulapu P, McNamara CA. B cells and atherosclerosis. *American Journal of Physiology-
884 Heart and Circulatory Physiology*. 2017;312(5):H1060-H7.
- 885 31. Tay C, Liu Y-H, Hosseini H, Kanellakis P, Cao A, Peter K, et al. B-cell-specific depletion of
886 tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by
887 reducing cell death and inflammation. *Cardiovascular Research*. 2016;111(4):385-97.
- 888 32. Tay C, Liu Y-H, Kanellakis P, Kallies A, Li Y, Cao A, et al. Follicular B Cells Promote
889 Atherosclerosis via T Cell-Mediated Differentiation Into Plasma Cells and Secreting Pathogenic
890 Immunoglobulin G. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2018;38(5):e71-e84.
- 891 33. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in
892 atherosclerosis. *Circ Res*. 2014;114(11):1743-56.
- 893 34. Weber C, Zerneck A, Libby P. The multifaceted contributions of leukocyte subsets to
894 atherosclerosis: lessons from mouse models. *Nat Rev Immunol*. 2008;8(10):802-15.
- 895 35. Zerneck A, Winkels H, Cochain C, Williams JW, Wolf D, Soehnlein O, et al. Meta-Analysis of
896 Leukocyte Diversity in Atherosclerotic Mouse Aortas. *Circ Res*. 2020;127(3):402-26.
- 897 36. Kazer SW, Aicher TP, Muema DM, Carroll SL, Ordovas-Montanes J, Miao VN, et al. Integrated
898 single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection. *Nature*
899 *Medicine*. 2020;26(4):511-8.

- 900 37. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data
901 across different conditions, technologies, and species. *Nat Biotechnol.* 2018;36(5):411-20.
- 902 38. Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, et al. MAST: a flexible
903 statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell
904 RNA sequencing data. *Genome Biol.* 2015;16:278.
- 905 39. Diaz-Mejia JJ, Meng EC, Pico AR, MacParland SA, Ketela T, Pugh TJ, et al. Evaluation of
906 methods to assign cell type labels to cell clusters from single-cell RNA-sequencing data. *F1000Res.*
907 2019;8.
- 908 40. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell
909 subsets from tissue expression profiles. *Nat Methods.* 2015;12(5):453-7.
- 910 41. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool
911 for interpreting omics data. *Innovation (N Y).* 2021;2(3):100141.
- 912 42. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular
913 Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* 2015;1(6):417-25.
- 914 43. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses
915 and cellular organisms. *Nucleic acids research.* 2021;49(D1):D545-d51.
- 916 44. Martens M, Ammar A, Riutta A, Waagmeester A, Slenter DN, Hanspers K, et al. WikiPathways:
917 connecting communities. *Nucleic acids research.* 2021;49(D1):D613-d21.
- 918 45. Palshikar MG, Hilchey SP, Zand MS, Thakar J. WikiNetworks: translating manually created
919 biological pathways for topological analysis. *Bioinformatics.* 2021.
- 920 46. Palli R, Palshikar MG, Thakar J. Executable pathway analysis using ensemble discrete-state
921 modeling for large-scale data. *Plos Computational Biology.* 2019;15(9).
- 922 47. Fortin F-A, De Rainville F-M, Gardner M-AG, Parizeau M, Gagné C. DEAP: Evolutionary
923 algorithms made easy. *The Journal of Machine Learning Research.* 2012;13(1):2171-5.
- 924 48. Méndez A, Mendoza L. A Network Model to Describe the Terminal Differentiation of B Cells.
925 *PLoS Comput Biol.* 2016;12(1):e1004696.
- 926 49. Martínez-Méndez D, Villarreal C, Mendoza L, Huerta L. An Integrative Network Modeling
927 Approach to T CD4 Cell Activation. *Front Physiol.* 2020;11:380.
- 928 50. Palma A, Jarrah AS, Tieri P, Cesareni G, Castiglione F. Gene Regulatory Network Modeling of
929 Macrophage Differentiation Corroborates the Continuum Hypothesis of Polarization States. *Front*
930 *Physiol.* 2018;9:1659.
- 931 51. Schwab JD, Ikonomi N, Werle SD, Weidner FM, Geiger H, Kestler HA. Reconstructing Boolean
932 network ensembles from single-cell data for unraveling dynamics in the aging of human hematopoietic
933 stem cells. *Comput Struct Biotechnol J.* 2021;19:5321-32.
- 934 52. Bäck M, Yurdagul A, Jr., Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in
935 atherosclerosis: mediators and therapeutic opportunities. *Nature reviews Cardiology.* 2019;16(7):389-406.
- 936 53. Negreiros-Lima GL, Lima KM, Moreira IZ, Jardim BLO, Vago JP, Galvão I, et al. Cyclic AMP
937 Regulates Key Features of Macrophages via PKA: Recruitment, Reprogramming and Efferocytosis. *Cells.*
938 2020;9(1).
- 939 54. Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling
940 in liver health and disease. *Cell Signal.* 2018;49:105-15.
- 941 55. Sugimoto MA, Vago JP, Perretti M, Teixeira MM. Mediators of the Resolution of the
942 Inflammatory Response. *Trends Immunol.* 2019;40(3):212-27.
- 943 56. Dalli J, Serhan CN. Pro-Resolving Mediators in Regulating and Conferring Macrophage
944 Function. *Front Immunol.* 2017;8:1400.
- 945 57. Lorenowicz MJ, Fernandez-Borja M, Hordijk PL. cAMP signaling in leukocyte transendothelial
946 migration. *Arterioscler Thromb Vasc Biol.* 2007;27(5):1014-22.
- 947 58. Gewaltig J, Kummer M, Koella C, Cathomas G, Biedermann BC. Requirements for CD8 T-cell
948 migration into the human arterial wall. *Human Pathology.* 2008;39(12):1756-62.

- 949 59. Hayakawa E, Yoshimoto T, Sekizawa N, Sugiyama T, Hirata Y. Overexpression of receptor for
950 advanced glycation end products induces monocyte chemoattractant protein-1 expression in rat vascular
951 smooth muscle cell line. *J Atheroscler Thromb*. 2012;19(1):13-22.
- 952 60. Athanasiadis EI, Botthof JG, Andres H, Ferreira L, Lio P, Cvejic A. Single-cell RNA-sequencing
953 uncovers transcriptional states and fate decisions in haematopoiesis. *Nature Communications*.
954 2017;8(1):2045.
- 955 61. Iadevaia V, Huo Y, Zhang Z, Foster Leonard J, Proud Christopher G. Roles of the mammalian
956 target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis. *Biochemical*
957 *Society Transactions*. 2012;40(1):168-72.
- 958 62. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, et al. The mTOR/PI3K and
959 MAPK pathways converge on eIF4B to control its phosphorylation and activity. *EMBO J*.
960 2006;25(12):2781-91.
- 961 63. Rosario FJ, Powell TL, Gupta MB, Cox L, Jansson T. mTORC1 Transcriptional Regulation of
962 Ribosome Subunits, Protein Synthesis, and Molecular Transport in Primary Human Trophoblast Cells.
963 *Frontiers in Cell and Developmental Biology*. 2020;8.
- 964 64. Chau KF, Shannon ML, Fame RM, Fonseca E, Mullan H, Johnson MB, et al. Downregulation of
965 ribosome biogenesis during early forebrain development. *eLife*. 2018;7:e36998.
- 966 65. Grönberg C, Nilsson J, Wigren M. Recent advances on CD4+ T cells in atherosclerosis and its
967 implications for therapy. *European Journal of Pharmacology*. 2017;816:58-66.
- 968 66. Zhao Y, Qian Y, Sun Z, Shen X, Cai Y, Li L, et al. Role of PI3K in the Progression and
969 Regression of Atherosclerosis. *Frontiers in Pharmacology*. 2021;12.
- 970 67. Flynn MC, Pernes G, Lee MKS, Nagareddy PR, Murphy AJ. Monocytes, Macrophages, and
971 Metabolic Disease in Atherosclerosis. *Front Pharmacol*. 2019;10:666.
- 972 68. Gupta Rajat M, Lee-Kim Vivian S, Libby P. The March of Monocytes in Atherosclerosis. *Circ*
973 *Res*. 2020;126(10):1324-6.
- 974 69. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis.
975 *Arterioscler Thromb Vasc Biol*. 2011;31(7):1506-16.
- 976 70. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived
977 cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. *Proceedings of*
978 *the National Academy of Sciences of the United States of America*. 2004;101(32):11779-84.
- 979 71. Merino A, Buendia P, Martin-Malo A, Aljama P, Ramirez R, Carracedo J. Senescent
980 CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. *J Immunol*.
981 2011;186(3):1809-15.
- 982 72. Ong S-M, Hadadi E, Dang T-M, Yeap W-H, Tan CT-Y, Ng T-P, et al. The pro-inflammatory
983 phenotype of the human non-classical monocyte subset is attributed to senescence. *Cell Death & Disease*.
984 2018;9(3):266.
- 985 73. Rafieian-Kopaei M, Setorki M, Douidi M, Baradaran A, Nasri H. Atherosclerosis: process,
986 indicators, risk factors and new hopes. *Int J Prev Med*. 2014;5(8):927-46.
- 987 74. Randolph GJ. The fate of monocytes in atherosclerosis. *J Thromb Haemost*. 2009;7 Suppl
988 1(Suppl 1):28-30.
- 989 75. Wilson HM. Macrophages heterogeneity in atherosclerosis - implications for therapy. *J Cell Mol*
990 *Med*. 2010;14(8):2055-65.
- 991 76. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. *Nature reviews*
992 *Cardiology*. 2010;7(2):77-86.
- 993 77. Gerhardt T, Ley K. Monocyte trafficking across the vessel wall. *Cardiovasc Res*.
994 2015;107(3):321-30.
- 995 78. Taylor JP, Tse HM. The role of NADPH oxidases in infectious and inflammatory diseases. *Redox*
996 *Biology*. 2021;48:102159.
- 997 79. Zhang J, Li H, Wu Q, Chen Y, Deng Y, Yang Z, et al. Tumoral NOX4 recruits M2 tumor-
998 associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote
999 NSCLC growth. *Redox Biology*. 2019;22:101116.

- 1000 80. Hao JJ, Liu Y, Kruhlak M, Debell KE, Rellahan BL, Shaw S. Phospholipase C-mediated
1001 hydrolysis of PIP2 releases ERM proteins from lymphocyte membrane. *J Cell Biol.* 2009;184(3):451-62.
- 1002 81. Gupta N, Wollscheid B, Watts JD, Scheer B, Aebersold R, DeFranco AL. Quantitative proteomic
1003 analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor-mediated lipid raft dynamics. *Nat*
1004 *Immunol.* 2006;7(6):625-33.
- 1005 82. Parameswaran N, Matsui K, Gupta N. Conformational switching in ezrin regulates morphological
1006 and cytoskeletal changes required for B cell chemotaxis. *J Immunol.* 2011;186(7):4088-97.
- 1007 83. Bradley JR. TNF-mediated inflammatory disease. *The Journal of Pathology.* 2008;214(2):149-60.
- 1008 84. Mehta AK, Gracias DT, Croft M. TNF activity and T cells. *Cytokine.* 2018;101:14-8.
- 1009 85. Jones SJ, Ledgerwood EC, Prins JB, Galbraith J, Johnson DR, Pober JS, et al. TNF recruits
1010 TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of
1011 TNF-R1. *J Immunol.* 1999;162(2):1042-8.
- 1012 86. Zhang Q, Cui F, Fang L, Hong J, Zheng B, Zhang JZ. TNF- α impairs differentiation and function
1013 of TGF- β -induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. *J Mol*
1014 *Cell Biol.* 2013;5(2):85-98.
- 1015 87. Azari BM, Marmur JD, Salifu MO, Ehrlich YH, Kornecki E, Babinska A. Transcription and
1016 translation of human F11R gene are required for an initial step of atherosclerosis induced by inflammatory
1017 cytokines. *Journal of Translational Medicine.* 2011;9(1):98.
- 1018 88. Theilmeyer G, Michiels C, Spaepen E, Vreys I, Collen D, Vermynen J, et al. Endothelial von
1019 Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.
1020 *Blood.* 2002;99(12):4486-93.
- 1021 89. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, et al. A critical role of platelet
1022 adhesion in the initiation of atherosclerotic lesion formation. *J Exp Med.* 2002;196(7):887-96.
- 1023 90. Woodfin A, Voisin M-B, Nourshargh S. PECAM-1: A Multi-Functional Molecule in
1024 Inflammation and Vascular Biology. *Arteriosclerosis, Thrombosis, and Vascular Biology.*
1025 2007;27(12):2514-23.
- 1026 91. Stevens HY, Melchior B, Bell KS, Yun S, Yeh JC, Frangos JA. PECAM-1 is a critical mediator
1027 of atherosclerosis. *Dis Model Mech.* 2008;1(2-3):175-81; discussion 9.
- 1028 92. Caligiuri G. CD31 as a Therapeutic Target in Atherosclerosis. *Circ Res.* 2020;126(9):1178-89.
- 1029 93. Cornwell A, Palli R, Singh MV, Benoodt L, Tyrell A, Abe JI, et al. Molecular characterization of
1030 atherosclerosis in HIV positive persons. *Sci Rep.* 2021;11(1):3232.
- 1031 94. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. *Nature Reviews*
1032 *Cardiology.* 2020;17(7):387-401.
- 1033 95. Reed JC, Preston-Hurlburt P, Philbrick W, Betancur G, Korah M, Lucas C, et al. The receptor for
1034 advanced glycation endproducts (RAGE) modulates T cell signaling. *PLOS ONE.* 2020;15(9):e0236921.
- 1035 96. Schäfer S, Zerneck A. CD8(+) T Cells in Atherosclerosis. *Cells.* 2020;10(1).
- 1036 97. van Duijn J, Kritikou E, Benne N, van der Heijden T, van Puijvelde GH, Kroner MJ, et al. CD8+
1037 T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and
1038 CD4+ T-cell responses. *Cardiovasc Res.* 2019;115(4):729-38.
- 1039 98. van Duijn J, Kuiper J, Slutter B. The many faces of CD8+ T cells in atherosclerosis. *Current*
1040 *opinion in lipidology.* 2018;29(5):411-6.
- 1041 99. Cochain C, Zerneck A. Protective and pathogenic roles of CD8(+) T cells in atherosclerosis.
1042 *Basic research in cardiology.* 2016;111(6):71.
- 1043 100. Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, et al. CD4+/CD8+ ratio, age,
1044 and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. *AIDS*
1045 (London, England). 2016;30(6):899-908.
- 1046 101. Flynn MC, Pernes G, Lee MKS, Nagareddy PR, Murphy AJ. Monocytes, Macrophages, and
1047 Metabolic Disease in Atherosclerosis. *Frontiers in Pharmacology.* 2019;10(666).
- 1048 102. Cochain C, Zerneck A. Macrophages and immune cells in atherosclerosis: recent advances and
1049 novel concepts. *Basic research in cardiology.* 2015;110(4):34.

- 1050 103. Shrestha S, Irvin MR, Grunfeld C, Arnett DK. HIV, inflammation, and calcium in atherosclerosis.
1051 *Arterioscler Thromb Vasc Biol.* 2014;34(2):244-50.
- 1052 104. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The
1053 macrophage: the intersection between HIV infection and atherosclerosis. *J Leukoc Biol.* 2010;87(4):589-
1054 98.
- 1055 105. Bianchi ME, Mezzapelle R. The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue
1056 Regeneration. *Frontiers in Immunology.* 2020;11.
- 1057 106. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14
1058 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. *Nat Med.*
1059 2007;13(9):1042-9.
- 1060 107. Crowe LAN, McLean M, Kitson SM, Melchor EG, Patommel K, Cao HM, et al. S100A8 &
1061 S100A9: Alarmin mediated inflammation in tendinopathy. *Sci Rep.* 2019;9(1):1463.
- 1062 108. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublotte JT, Raychowdhury R, et al. Single-
1063 cell transcriptomics reveals bimodality in expression and splicing in immune cells. *Nature.*
1064 2013;498(7453):236-40.
- 1065 109. Trinh H-C, Kwon Y-K. A novel constrained genetic algorithm-based Boolean network inference
1066 method from steady-state gene expression data. *Bioinformatics.* 2021;37(Supplement_1):i383-i91.
- 1067 110. Lim CY, Wang H, Woodhouse S, Piterman N, Wernisch L, Fisher J, et al. BTR: training
1068 asynchronous Boolean models using single-cell expression data. *BMC Bioinformatics.* 2016;17(1):355.
- 1069 111. Egaña-Gorroño L, López-Díez R, Yepuri G, Ramirez LS, Reverdatto S, Gugger PF, et al.
1070 Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities
1071 in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models. *Front*
1072 *Cardiovasc Med.* 2020;7:37.
- 1073 112. Kosmopoulos M, Drekolias D, Zavras PD, Piperi C, Papavassiliou AG. Impact of advanced
1074 glycation end products (AGEs) signaling in coronary artery disease. *Biochimica et Biophysica Acta*
1075 *(BBA) - Molecular Basis of Disease.* 2019;1865(3):611-9.
- 1076 113. Narumi K, Miyakawa R, Ueda R, Hashimoto H, Yamamoto Y, Yoshida T, et al. Proinflammatory
1077 Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE. *The Journal of Immunology.*
1078 2015;194(11):5539-48.
- 1079 114. Hofmann Bowman MA, Schmidt AM. S100/calgranulins EN-RAGEing the blood vessels:
1080 implications for inflammatory responses and atherosclerosis. *Am J Cardiovasc Dis.* 2011;1(1):92-100.
- 1081 115. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and
1082 diabetes. *Clin Sci (Lond).* 2011;121(2):43-55.
- 1083 116. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE)
1084 and cardiovascular disease. *Expert Rev Mol Med.* 2009;11:e9.
- 1085 117. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for
1086 Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. *Journal of*
1087 *Translational Medicine.* 2009;7(1):17.
- 1088 118. Nienhuis HL, Westra J, Smit AJ, Limburg PC, Kallenberg CG, Bijl M. AGE and their receptor
1089 RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated
1090 atherosclerosis. *Autoimmunity.* 2009;42(4):302-4.
- 1091 119. Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE/RAGE axis in diabetes-accelerated
1092 atherosclerosis. *Clin Exp Pharmacol Physiol.* 2008;35(3):329-34.
- 1093 120. Li H, Zhang L, Yin D, Zhang Y, Miao J. Targeting Phosphatidylcholine-Specific Phospholipase
1094 C for Atherogenesis Therapy. *Trends in Cardiovascular Medicine.* 2010;20(5):172-6.
- 1095 121. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. *Curr*
1096 *Pharm Des.* 2009;15(27):3108-15.
- 1097 122. Hartmann S, Ridley AJ, Lutz S. The Function of Rho-Associated Kinases ROCK1 and ROCK2 in
1098 the Pathogenesis of Cardiovascular Disease. *Front Pharmacol.* 2015;6:276.
- 1099 123. Cai A, Zhou Y, Li L. Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins. *J Am Heart*
1100 *Assoc.* 2015;4(7).

- 1101 124. Jin SY, Kim EK, Ha JM, Lee DH, Kim JS, Kim IY, et al. Insulin regulates monocyte trans-
1102 endothelial migration through surface expression of macrophage-1 antigen. *Biochim Biophys Acta*.
1103 2014;1842(9):1539-48.
- 1104 125. Zhou Y, Wang Y, Qiao S, Yin L. Effects of Apelin on Cardiovascular Aging. *Frontiers in*
1105 *Physiology*. 2017;8.
- 1106 126. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart
1107 failure and atherosclerosis in man. *British Journal of Pharmacology*. 2010;160(7):1785-95.
- 1108 127. Ahrens TD, Bang-Christensen SR, Jørgensen AM, Løppke C, Spliid CB, Sand NT, et al. The
1109 Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis. *Front Cell Dev Biol*.
1110 2020;8:749.
- 1111 128. Edwards IJ. Proteoglycans in prostate cancer. *Nat Rev Urol*. 2012;9(4):196-206.
- 1112 129. Aberle H. Axon Guidance and Collective Cell Migration by Substrate-Derived Attractants. *Front*
1113 *Mol Neurosci*. 2019;12:148.
- 1114 130. Russell SA, Bashaw GJ. Axon guidance pathways and the control of gene expression. *Dev Dyn*.
1115 2018;247(4):571-80.
- 1116 131. Tavares LP, Negreiros-Lima GL, Lima KM, E Silva PMR, Pinho V, Teixeira MM, et al. Blame
1117 the signaling: Role of cAMP for the resolution of inflammation. *Pharmacological Research*.
1118 2020;159:105030.
- 1119 132. Huang S. Reprogramming cell fates: reconciling rarity with robustness. *BioEssays : news and*
1120 *reviews in molecular, cellular and developmental biology*. 2009;31(5):546-60.
- 1121 133. Huang S, Eichler G, Bar-Yam Y, Ingber DE. Cell fates as high-dimensional attractor states of a
1122 complex gene regulatory network. *Physical review letters*. 2005;94(12):128701.
- 1123 134. Huang S, Ernberg I, Kauffman S. Cancer attractors: a systems view of tumors from a gene
1124 network dynamics and developmental perspective. *Seminars in cell & developmental biology*.
1125 2009;20(7):869-76.
- 1126 135. Taherian Fard A, Ragan MA. Modeling the Attractor Landscape of Disease Progression: a
1127 Network-Based Approach. *Front Genet*. 2017;8:48.
- 1128 136. Uthamacumaran A. A review of dynamical systems approaches for the detection of chaotic
1129 attractors in cancer networks. *Patterns (N Y)*. 2021;2(4):100226.
- 1130 137. Trapnell C. Defining cell types and states with single-cell genomics. *Genome Res*.
1131 2015;25(10):1491-8.
- 1132 138. Munsky B, Neuert G, van Oudenaarden A. Using gene expression noise to understand gene
1133 regulation. *Science (New York, NY)*. 2012;336(6078):183-7.
- 1134 139. Liu S, Trapnell C. Single-cell transcriptome sequencing: recent advances and remaining
1135 challenges. *F1000Research*. 2016;5:F1000 Faculty Rev-182.
- 1136 140. Tsai S, Clemente-Casares X, Zhou AC, Lei H, Ahn JJ, Chan YT, et al. Insulin Receptor-Mediated
1137 Stimulation Boosts T Cell Immunity during Inflammation and Infection. *Cell Metab*. 2018;28(6):922-
1138 34.e4.
- 1139 141. Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, et al. PD1 signal
1140 transduction pathways in T cells. *Oncotarget*. 2017;8(31):51936-45.
- 1141 142. Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells
1142 in the tumor microenvironment. *Cellular & Molecular Immunology*. 2020;17(1):27-35.
- 1143 143. Yi H-S, Kim SY, Kim JT, Lee Y-S, Moon JS, Kim M, et al. T-cell senescence contributes to
1144 abnormal glucose homeostasis in humans and mice. *Cell Death & Disease*. 2019;10(3):249.
- 1145 144. McLaughlin T, Liu L-F, Lamendola C, Shen L, Morton J, Rivas H, et al. T-cell profile in adipose
1146 tissue is associated with insulin resistance and systemic inflammation in humans. *Arteriosclerosis,*
1147 *thrombosis, and vascular biology*. 2014;34(12):2637-43.
- 1148 145. Singh MV, Kotla S, Le N-T, Ae Ko K, Heo K-S, Wang Y, et al. Senescent Phenotype Induced by
1149 p90RSK-NRF2 Signaling Sensitizes Monocytes and Macrophages to Oxidative Stress in HIV-Positive
1150 Individuals. *Circulation*. 2019;139(9):1199-216.

- 1151 146. Rattan V, Shen Y, Sultana C, Kumar D, Kalra VK. Glucose-induced transmigration of monocytes
1152 is linked to phosphorylation of PECAM-1 in cultured endothelial cells. *American Journal of Physiology-*
1153 *Endocrinology and Metabolism*. 1996;271(4):E711-E7.
- 1154 147. Okouchi M, Okayama N, Imai S, Omi H, Shimizu M, Fukutomi T, et al. High insulin enhances
1155 neutrophil transendothelial migration through increasing surface expression of platelet endothelial cell
1156 adhesion molecule-1 via activation of mitogen activated protein kinase. *Diabetologia*. 2002;45(10):1449-
1157 56.
- 1158 148. Kharchenko PV, Silberstein L, Scadden DT. Bayesian approach to single-cell differential
1159 expression analysis. *Nature methods*. 2014;11(7):740-2.
- 1160 149. Brorson IS, Eriksson A, Leikfoss IS, Celius EG, Berg-Hansen P, Barcellos LF, et al. No
1161 differential gene expression for CD4(+) T cells of MS patients and healthy controls. *Mult Scler J Exp*
1162 *Transl Clin*. 2019;5(2):2055217319856903-.

1163

1164

1165 **Supplementary Material**

1166 **1. Supplementary File 1:**

- 1167 • **Filename:** *supplementary_file_1.pdf*
- 1168 • **Description:** Contains Supplementary Figures 1 – 6 and corresponding captions.

1169 **2. Supplementary Table 1:**

- 1170 • **Filename:** *supplementary_table_1.txt*
- 1171 • **Description of Supplementary Table 1:** Cluster markers for each subpopulation
1172 identified in PBMCs derived from AS+ and AS- PLWH are listed in the file
1173 “*supplementary_table_1.csv*”. Cluster markers were identified using methods
1174 implemented in the Seurat R package, as described in the methods.

1175 **3. Supplementary Table 2:**

- 1176 • **Filename:** *supplementary_table_2.xlsx*
- 1177 • **Description of supplementary table 2:** *supplementary_table_2* contains 2 worksheets,
1178 “DE genes in AS+ vs AS-” and “*enrichr_kegg*”. “DE genes in AS+ vs AS-” contains a
1179 table of genes differentially expressed between cells derived from AS+ and AS- PLWH
1180 for each subpopulation in the HIV/AS dataset. The sheet “*enrichr_kegg*” contains a table
1181 of KEGG gene sets enriched (identified using the *enrichr* R package) in the DE genes
1182 from “DE genes in AS+ vs AS-”.

1183 **4. Supplementary Table 3:**

- 1184 • **Filename:** *supplementary_table_3.txt*
- 1185 • **Description of Supplementary Table 3:** scBONITA infers biologically meaningful
1186 dysregulated pathways for subpopulations of PBMCs derived from AS+ and AS- PLWH
1187 in the HIVAS/HIVAS- contrast. The table of dysregulated pathways identified by
1188 scBONITA in the HIV+/AS+ - HIV+/AS- contrast in all cell clusters is presented in the
1189 CSV file titled “*supplementary_table_3.txt*”.

1190 5. **Supplementary Table 4**

- 1191 • **Filename:** *supplementary_table_4.txt*
- 1192 • **Description:** Pearson correlation coefficients between importance scores for networks
- 1193 trained on subpopulations of PBMCs from the Kazer et al dataset and trained on the
- 1194 corresponding subpopulations from the HIV/AS dataset. All p values are < 0.01.


1195 6. **Supplementary Table 5**

- 1196 • **Filename:** *supplementary_table_5.txt*
- 1197 • **Description:** scBONITA infers biologically meaningful dysregulated pathways for
- 1198 subpopulations of PBMCs derived from HIV- subjects and subjects after 1 year of HIV
- 1199 infection (Kazer et al). The CSV file *supplementary_table_5.txt* lists the dysregulated
- 1200 pathways and p-values from scBONITA for every subpopulation.

1201 7. **Supplementary Table 6**

- 1202 • **Filename:** *supplementary_table_6.txt*
- 1203 • **Description:** Comparison of dysregulated pathways, as identified by scBONITA,
- 1204 between subpopulations of PBMCs derived from HIV- subjects and subjects after 1 year
- 1205 of HIV infection (Kazer et al) and subpopulations of PBMCs derived from HIV+ subjects
- 1206 with and without atherosclerosis. The file *supplementary_table_6.txt* lists the
- 1207 dysregulated pathways for subpopulations from the Kazer et al dataset and the
- 1208 corresponding subpopulations from the HIV/AS dataset, along with the intersections
- 1209 between the pathways dysregulated in the two contrasts. We speculate that intersecting
- 1210 pathways and the pathways dysregulated in the HIV/AS contrast are driven by HIV-
- 1211 associated inflammatory processes. Similarly, pathways that are dysregulated only in the
- 1212 HIV-/HIV+ contrast are assumed to be driven by the immediate antiviral response to HIV
- 1213 infection.

1214 **Figures**



1215

1216 **Figure 1:** Characterization of PBMC subpopulations in people living with HIV (PLWH) with (AS+) or

1217 without atherosclerosis (AS-) (A) t-SNE projection of 16 transcriptionally distinct cell subpopulations,

1218 shown in distinct colors. Cell clusters are characterized and labeled based on the expression of canonical

1219 markers, using CIBERSORT. (B) Subpopulation-level differences between AS+ and AS- PLWH are


1220 identified using a t-test. Panels C - F show the expression of genes that are differentially expressed (DE)

1221 between cells derived from AS+ and AS- subjects. DE genes were identified using the Wilcoxon test

1222 (Bonferroni-adjusted p-value < 0.1, absolute log₂ fold change > 0.3.) DE genes between AS+ and AS-


1223 cells in (C) CD8 T cells/NK resting cells, (D) monocytes, (E) naïve B cells referred to as "B cells naïve -

1224 2" in panels A and B, and (F) T cells referred to as "T cells CD8/CD4/CD4 naïve" in panels A and B.



1225

1226 **Figure 2:** scBONITA pipeline to infer Boolean rules and perform pathway analysis using single cell
1227 expression measurements (A) **Input:** scBONITA requires a binarized single-cell RNA-seq dataset as a
1228 text file, and a prior knowledge network (PKN) describing the activating or inhibitory relationships
1229 between genes (B) **Rule determination:** scBONITA infers logic rules that describe the regulatory
1230 relationships between nodes in the PKN by a global search followed by node-level rule refinement (C)
1231 **Pathway analysis:** scBONITA calculates a gene importance score calculated by simulating network
1232 perturbations with inferred rules and combines these scores with fold-changes from scRNA-seq to
1233 identify dysregulated pathways in a specified contrast (D) **Steady-state analysis:** scBONITA simulates
1234 networks using learned rules to identify steady states which correspond to observed cellular states.



1235

1236 **Figure 3:** scBONITA identifies dysregulated pathways in T cells derived from AS+ and AS- PLWH. (A)

1237 Pathways (y-axis) dysregulated in the AS+ vs AS- contrast in PLWH in clusters of CD8+ T cells. Clusters

1238 are differentiated by point shape, as shown in the legend. Pathways that have Bonferroni-corrected p-

1239 value < 0.01 (x-axis) and a reduced ERS (see Methods for details) are shown. Pathways labeled with

1240 “***” were also significantly dysregulated between cytotoxic T cells derived from HIV- subjects and

1241 subjects after 1 year of HIV infection (36) (B) (Pathways (y-axis) dysregulated in the AS+ vs AS-

1242 contrast in PLWH in clusters of CD4+ T cells and naïve T cells. Clusters are differentiated by point

1243 shape, as shown in the legend. Pathways that have Bonferroni-corrected p-value < 0.01 (x-axis) and a

1244 reduced ERS (see Methods for details) are shown. Pathways labeled with “***” were also significantly

1245 dysregulated between T cells derived from HIV- subjects and subjects after 1 year of HIV infection (36)

1246 (C) Network representation of the AGE-RAGE signaling pathway (Bonferroni-corrected p-value < 0.01)

1247 in a cluster of CD8+ T cells referred to as CD8 T cells -1 in Figure 1A. Small black intermediate nodes


1248 indicate that the downstream nodes are controlled by an AND function of the upstream nodes. The size of

1249 nodes corresponding to genes is proportional to their importance score calculated by scBONITA. Nodes

1250 are colored according to the magnitude of their fold change between the HIV+AS+ and HIV+AS- groups.

1251 Violet edges indicate inhibition edges and black edges indicate activation edges.

1252



1253

1254

Figure 4: scBONITA identifies dysregulated pathways in monocytes derived from AS+ and AS- PLWH:

1255

(A) Pathways (y-axis) dysregulated in the AS+ vs AS- contrast in monocytes derived from PLWH. Only

1256

pathways that have Bonferroni-corrected p-value < 0.01 (x-axis) and which have a reduced ERS (see

1257

Methods for details) are shown. Pathways labeled with “***” were also significantly dysregulated in

1258

monocytes after one year of HIV infection (36) (B) Network representation of the leukocyte

1259

transendothelial migration pathway. Small black intermediate nodes indicate that the downstream nodes

1260

are controlled by an AND function of the upstream nodes. The size of nodes corresponding to genes is

1261

proportional to their importance score as calculated by scBONITA. Nodes are colored according to the


1262

magnitude of their fold change between the HIV+AS+ and HIV+AS- groups. Violet edges indicate

1263

inhibition edges and black edges indicate activation edges.

1264



1265

1266


1267 **Figure 5:** CD8+ T cell states with respect to the insulin resistance pathway identified by attractor analysis

1268 with scBONITA. (A) UMAP representation of a cluster of CD8+ T cells (CD8+ T cells – 1 in Figure 1A)

1269 colored by the attractor to which they are assigned, based on their similarity. The three dominant states

1270 (PI3KR+ PI3K+, TNFR1+TNF- and TNFR1-TNF+ attractors) are represented by green, blue and orange.

1271 All other attractors are collectively labeled in grey. (B) Percentages of CD8+ T cells derived from each
1272 subject, mapping to the three dominant and all other attractors. (C) Gene activity (ON- red, OFF- light
1273 blue) in the three dominant attractors. Only genes that are different between these states are shown. (D)
1274 Attractor gene values ranging from 0 (blue) to 1 (red) averaged for each individual subject. The top bar
1275 indicates AS+ (grey) and AS- (black) subjects.
1276



1277

1278 **Figure 6:** Monocyte states with respect to the leukocyte transendothelial migration pathway identified by

1279 attractor analysis with scBONITA. (A) UMAP representation of the cluster of monocytes colored by the

1280 attractor to which they are assigned, based on their similarity. The two dominant modes (F11R+ and

1281 PECAM+ attractors) are represented by blue and orange. All other attractors are collectively labeled in

1282 grey. (B) Percentages of monocytes derived from each subject, mapping to the two dominant attractors

1283 and all other attractors for the leukocyte transendothelial migration pathway. (C) Attractor gene values


1284 for the for the leukocyte transendothelial migration pathway trained on monocytes, ranging from 0 (blue)

1285 to 1 (red), averaged for each individual subjects. The top bar indicates AS+ (grey) and AS- (black)

1286 subjects. The genes that differ between the two dominant attractors F11R+ and PECAM+ are highlighted

1287 by a violet box.

1288



1289
 1290 **Figure 7:** Performance of scBONITA rule determination. (A) The number of pathways identified as
 1291 significantly dysregulated (Bonferroni-adjusted p value < 0.05) one year upon HIV infection(36),
 1292 between AS+ and AS- PLWH, and the intersections between these sets. Subpopulations from the two
 1293 datasets were matched as shown in Supplementary Table 5. (B) Effects of number of cells on the ERS
 1294 size evaluated by downsampling and augmentation using the largest cluster (“B cells naïve – 1”) from the
 1295 HIV/AS dataset (C) Relation between importance scores in 130 KEGG networks evaluated using CD8+ T
 1296 cells from AS+ and AS- PLWH and from persons before and one year after HIV infection (36). (D)
 1297 Spearman correlations (p < 0.01 for all comparisons) between scBONITA’s node importance score
 1298 (labeled as ‘scBONITA score’) and 6 measures of node centrality (along x and y axis). Correlation
 1299 coefficients are depicted by colors ranging from blue (-1) to red (+1).